


MPM BIOVENTURES III-QP L.P. Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      MPM BIOVENTURES III-QP L.P.
                    

•   BOSTON, MA
                      
How do I update this listing?




                                             MPM Bioventures Iii-qp is based out of Boston.    WhaleWisdom has at least 18 13D/G filings in our database for MPM Bioventures Iii-qp.
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from MPM BIOVENTURES III-QP L.P., enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




mpm bioventures iii-qp l.p.


C/O MPM ASSET MANAGEMENT

BOSTON
MA
                                                        
                                                    02116


              Business Phone:
              617 425 9200







Recent SEC Filings




SC 13D/A filed on 10/03/2016
4 filed on 09/29/2016
SC 13G/A filed on 02/05/2015
4 filed on 06/10/2014
SC 13G filed on 02/12/2014
SC 13D/A filed on 10/02/2012
SC 13D/A filed on 10/31/2011
SC 13D/A filed on 10/14/2011











Current 13D/G Holdings


Stock
Sector
Shares Held
Market Value
Rank
Source
Source Date





Enteromedics Inc (ETRM)


      HEALTH CARE
    

      1,823,411
    

      5,169,372,774.24
    

      1
    

      13D
    

      2010-12-14
    



EPIRUS BIOPHARMACEUTICALS INC COM (EPRSQ)


      HEALTH CARE
    

      11,016,888
    

      363,557,193.83
    

      2
    

      13D
    

      2013-04-23
    



RADIUS HEALTH (RDUS)


      HEALTH CARE
    

      4,111,022
    

      233,711,600.70
    

      3
    

      13D
    

      2016-09-27
    











Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free



















MPM BIOVENTURES III-QP L.P. - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











MPM BIOVENTURES III-QP L.P.
Check out list of companies and businesses related to MPM BIOVENTURES III-QP L.P.. Find out MPM BIOVENTURES III-QP L.P. address and contact details. View other people related to MPM BIOVENTURES III-QP L.P. - coworkers, colleagues, companions, etc.
Address:   

C/O MPM ASSET MANAGEMENT 200 CLARENDON ST., 54TH FLOOR BOSTON 02116 MA




Companies related to MPM BIOVENTURES III-QP L.P.
CIKCompany NamePositionCompany Address0001135906EPIRUS Biopharmaceuticals, Inc.699 BOYLSTON ST 8TH FLOOR BOSTON 021160001326190Altimmune, Inc.19 FIRSTFIELD ROAD  GAITHERSBURG 208780001339455Pernix Sleep, Inc.10% Owner 440 STEVENS AVENUE, SUITE 200 SOLANA BEACH 920750001371217EnteroMedics Inc10% Owner 2800 Patton Rd  St Paul 551130001410064ARYx Therapeutics, Inc.10% Owner 6300 DUMBARTON CIRCLE  FREMONT 945550001428522Radius Health, Inc.ATTN CHIEF FINANCIAL OFFICER 950 WINTER STREET WALTHAM 02451




MPM BIOVENTURES III-QP L.P. on the Web
Persons related to MPM BIOVENTURES III-QP L.P. - EPIRUS Biopharmaceuticals, Inc.NamePositionCity5AM Co-Investors III, L.P.MENLO PARK5AM Co-Investors III, L.P.MENLO PARK5AM Partners III, LLCMENLO PARK5AM Partners III, LLC10% Owner MENLO PARK5AM VENTURES III, L.P.MENLO PARK5AM VENTURES III, L.P.MENLO PARKRICHARD  ALDRICHBOSTONRICHARD  ALDRICHDirector CAMBRIDGEANGIOTECH PHARMACEUTICALS INCVANCOUVERANGIOTECH PHARMACEUTICALS INC VANCOUVERLYNN G  BAIRDSenior VP - Regulatory Affairs CAMBRIDGELYNN G  BAIRDSenior VP - Regulatory Affairs CAMBRIDGELYNN G  BAIRDSenior VP - Reg. Affairs CAMBRIDGELYNN G  BAIRDSenior VP - Regulatory Affairs CAMBRIDGELYNN G  BAIRDSVP, Regulatory Affairs CAMBRIDGEJOHN V  BALENROWAYTONBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGODAVID  BONDERMANFORT WORTHDAVID  BONDERMANFORT WORTH,Alexis  BorisyPresident & CEO BOSTONAlexis  BorisyCEO & President CAMBRIDGEAlexis  BorisyCEO & President CAMBRIDGEAlexis  BorisyCEO & President CAMBRIDGEJ KEVIN  BUCHIDirector J KEVIN  BUCHIDirector BOSTONBVF INC/ILCHICAGOBVF INC/ILSAN FRANCISCOBVF INC/ILCHICAGOBVF INVESTMENTS LLCCHICAGOBVF INVESTMENTS LLCCHICAGOBVF PARTNERS L P/IL10% Owner SAN FRANCISCOBVF PARTNERS L P/IL10% Owner CHICAGOBVF PARTNERS L P/ILCHICAGOCANAAN EQUITY II ENTREPRENEURS LLCROWAYTONCANAAN EQUITY II ENTREPRENEURS LLCROWAYTONCanaan Equity II, L.P. (QP)ROWAYTONCanaan Equity II, L.P. (QP)ROWAYTONCANAAN EQUITY II LPROWAYTONCANAAN EQUITY II LPROWAYTONCanaan Equity Partners II LLCROWAYTONCanaan Equity Partners II LLC10% Owner ROWAYTONCanaan Equity Partners II LLCROWAYTONCharmers Landing LLCROWAYTONGallen  ChristopherCAMBRIDGEDouglas  ColeDirector BOSTONJason  ColeSenior VP and General Counsel BOSTONJason  ColeSenior VP & General Counsel CAMBRIDGEJason  ColeSenior VP & Gen.Counsel CAMBRIDGEJason  ColeSenior VP & General Counsel CAMBRIDGEJason  ColeSVP & General Counsel CAMBRIDGEJason  ColeSenior VP & General Counsel CAMBRIDGEJason  ColeEVP,Corp Dev & General Counsel CAMBRIDGEMARK  CORRIGANDirector MARLBOROUGHMARK  CORRIGANDirector BOSTONMARK  CORRIGANPresident & CEO CAMBRIDGEMARK  CORRIGANDirector CAMBRIDGEMARK  CORRIGANPresident & CEO CAMBRIDGEJAMES G  COULTERFORT WORTHJAMES G  COULTERFORT WORTH,SALLY  CRAWFORDDirector CAMBRIDGESALLY  CRAWFORDDirector CAMBRIDGEKAMRA  DEEPAKROWAYTONMARK J  DENINOWAYNEBarbara  DeptulaDirector BOSTONBarbara  DeptulaDirector CAMBRIDGEBarbara  DeptulaDirector CAMBRIDGEJOHN D  DIEKMANMENLO PARKJOHN D  DIEKMANMENLO PARKGEOFFREY M  DUYKDirector GEOFFREY M  DUYKFORT WORTHTodd  FoleyCAMBRIDGETodd  FoleyDirector CAMBRIDGETodd  FoleyDirector CAMBRIDGERobert  ForresterExecutive VP & CFO BOSTONRobert  ForresterExecutive VP & CFO CAMBRIDGERobert  ForresterEVP and CFO CAMBRIDGERobert  ForresterEVP & CFO CAMBRIDGERobert  ForresterEVP & CFO CAMBRIDGERobert  ForresterEVP & CFO CAMBRIDGERobert  ForresterEVP and COO CAMBRIDGEPATRICK J  FORTUNEDirector BOSTONPATRICK J  FORTUNEDirector CAMBRIDGEPATRICK J  FORTUNEDirector CAMBRIDGEHaydu  FrankCAMBRIDGEDaotian  FuDirector GONGBEI ZHUHAI CITY, GUANGDONGJAMES C  FURNIVALLROWAYTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONChristopher C.  GallenEVP Research & Development CAMBRIDGEChristopher C.  GallenEVP, Research & Development CAMBRIDGEChristopher C.  GallenEVP Research & Development CAMBRIDGEJacob  GoldfieldDirector BOSTONDaniel  GrauSen. VP, Commercial Operations BOSTONDaniel  GrauChief Operating Officer CAMBRIDGEDaniel  GrauChief Operating Officer CAMBRIDGEDaniel  GrauChief Operating Officer CAMBRIDGEDaniel  GrauChief Operating Officer CAMBRIDGEL STEPHEN  GREENROWAYTONRichardson  HartleyCAMBRIDGEFRANK  HAYDUDirector CAMBRIDGEFRANK  HAYDUDirector CAMBRIDGEFRANK  HAYDUBOSTONFRANK  HAYDUDirector CAMBRIDGEFRANK  HAYDUDirector CAMBRIDGEDENNIS  HENNERBOSTONWilliam L  HunterDirector VANCOUVERWilliam L  HunterDirector CAMBRIDGEWilliam L  HunterDirector CAMBRIDGEWilliam L  HunterDirector CAMBRIDGEWilliam L  HunterDirector BOSTONCole  JasonCAMBRIDGERenz  JustinCAMBRIDGEMichael  KauffmanDirector CAMBRIDGEMichael  KauffmanDirector CAMBRIDGEMichael  KauffmanDirector CAMBRIDGEMichael  KauffmanDirector CAMBRIDGECurtis T  KeithSenior VP, Discovery BOSTONCurtis T  KeithSenior VP, Research CAMBRIDGECurtis T  KeithSVP, Research CAMBRIDGEROBERT E  KEITH JRWAYNEGREGORY  KOPCHINSKYROWAYTONMARK N  LAMPERTCHICAGOJan  LessemExecutive VP & CMO BOSTONJan  LessemExecutive VP & CMO CAMBRIDGELivzon MABPharm Inc.GONGBEI, ZHUHAI, GUANGDONGCorrigan  MarkCAMBRIDGER Eric  McAllisterSenior VP Clinical Development BOSTONJulie  McHughDirector CHADDS FORDJulie  McHughDirector BOSTONKauffman  MichaelCAMBRIDGECHRISTOPHER  MOLLERDirector WAYNEMONTREUX EQUITY PARTNERS IV LPSAN FRANCISCOMONTREUX EQUITY PARTNERS IV LP10% Owner SAN FRANCISCOMontreux Equity Partners V, L.P.SAN FRANCISCOMontreux Equity Partners V, L.P.SAN FRANCISCOMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM ASSET MANAGEMENT LLCBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONAmit  MunshiChief Executive Officer BOSTONWILLIAM J  OSHEADirector CAMBRIDGEWILLIAM J  OSHEADirector CAMBRIDGEWILLIAM J  OSHEADirector CAMBRIDGERICHARD F  POPSBOSTONRICHARD F  POPSDirector CAMBRIDGERICHARD F  POPSDirector CAMBRIDGEJohn  RandleCAMBRIDGEJohn  RandleSVP Commercial Development CAMBRIDGEJustin A  RenzCAMBRIDGEJustin A  RenzSVP & Chief Financial Officer CAMBRIDGEJustin A  RenzSVP & CFO CAMBRIDGEJustin A  RenzEVP, CFO & Treasurer CAMBRIDGEHartley T  RichardsonDirector CAMBRIDGEHartley T  RichardsonDirector CAMBRIDGEHartley T  RichardsonDirector CAMBRIDGESCOTT M  ROCKLAGEDirector LINCOLNSCOTT M  ROCKLAGEBOSTONSCOTT M  ROCKLAGEDirector BOSTONSETH  RUDNICKDirector BOSTONGUY M  RUSSOROWAYTONGUY M  RUSSOROWAYTONCrawford  SallyCAMBRIDGEAndrew J.  SchwabMENLO PARKAndrew J.  SchwabMENLO PARKKim  SethChief Business Officer BOSTONThomas A.  SheaChief Financial Officer BOSTONNICHOLAS J  SIMON IIIBOSTONTerrance P.  SnutchSVP & Chief Scientific Officer CAMBRIDGETerrance P.  SnutchSVP & CSO CAMBRIDGEMICHAEL  STEINMETZBOSTONStonehenge LLCROWAYTONRobert  TicktinGeneral Counsel BOSTONTL VENTURES V INTERFUND LPWAYNETL VENTURES V LLCWAYNETL VENTURES V LP10% Owner WAYNETL VENTURES V MANAGEMENT LPWAYNEFoley  ToddCAMBRIDGETPG Group Holdings (SBS) Advisors, Inc.10% Owner FORT WORTH,TPG Group Holdings (SBS) Advisors, Inc.FORT WORTHAurentz  VincentChief Business Officer BOSTONO'Shea  W.CAMBRIDGEWaubeeka LLCROWAYTONKURT  WHEELERBOSTONHunter  WilliamCAMBRIDGEC. Eugene  WrightSVP & Chief Dev Officer CAMBRIDGEC. Eugene  WrightDirector CAMBRIDGEMichael  WyandPresident and COO BOSTONERIC A  YOUNGROWAYTONERIC A  YOUNG10% Owner ROWAYTONPersons related to MPM BIOVENTURES III-QP L.P. - Altimmune, Inc.NamePositionCityERIC  AGUIARPRINCETONEdward B  BergerDES MOINESEdward B  BergerTUCSONChristopher C  CamutVP, Gov't Contracts ANNAPOLISJAMES H  CAVANAUGHDirector PRINCETONLINDA L  CHANGSVP, CFO & Secretary ANNAPOLISLINDA L  CHANGSVP, CFO & Secretary ANNAPOLISReinhart  Charles IIIAnnapolisCamut  ChristopherAnnapolisFrancesca M  CookSVP, Policy & Gov't Affairs ANNAPOLISFrancesca M  CookSVP, Policy & Gov't Affairs ANNAPOLISFrancesca M  CookSVP, Policy & Gov't Affairs ANNAPOLISELIZABETH  CZEREPAKSee Remarks GERMANTOWNELIZABETH  CZEREPAKDirector NEW YORKWright  DavidAnnapolisSchaffer  DeraceAnnapolisSchaffer  DeraceAnnapolisDavid  DrutzDirector RALEIGHISRAEL A  ENGLANDERNEW YORKWilliam  EnrightSee Remarks GAITHERSBURGRichman  EricAnnapolisRichman  EricAnnapolisCook  FrancescaAnnapolisCook  FrancescaAnnapolisPHIL  FROHLICHTULSAPHIL  FROHLICHTULSAPHIL  FROHLICHTULSAPHIL  FROHLICHTULSATHOMAS RICHARD  FUERSTEVP, Chief Scientific Officer ANNAPOLISJoan  FuscoSVP, Operations ANNAPOLISJoan  FuscoSVP, Operations ANNAPOLISANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONJOHN  GILLDirector ANNAPOLISJOHN  GILLDirector ANNAPOLISJOHN  GILLDirector ANNAPOLISJOHN  GILLDirector ANNAPOLISHealthCare Partners VII, L.P.PRINCETONHealthCare Partners VII, L.P.PRINCETONHEALTHCARE VENTURES VII LP10% Owner PRINCETONHEALTHCARE VENTURES VII LP10% Owner PRINCETONDENNIS  HENNERBOSTONPhilip  HodgesDirector GAITHERSBURGCavanaugh  JamesAnnapolisCavanaugh  JamesAnnapolisRunge  JeffreyAnnapolisFusco  JoanAnnapolisFusco  JoanAnnapolisMcCleary  JoelAnnapolisMcCleary  JoelAnnapolisGill  JohnAnnapolisGill  JohnAnnapolisPappajohn  JohnAnnapolisPappajohn  JohnAnnapolisJeffrey Michael  JonesCOO ANNAPOLISKarp  JordanAnnapolisKarp  JordanAnnapolisJordan P  KarpSVP, General Counsel ANNAPOLISJordan P  KarpSVP, General Counsel ANNAPOLISJordan P  KarpSVP, General Counsel ANNAPOLISMATTHEW P  KINLEYDES MOINESMATTHEW P  KINLEYPresident & Treasurer DES MOINESMATTHEW P  KINLEYPresident & Treasurer DES MOINESMATTHEW P  KINLEYPresident & Treasurer DES MOINESMATTHEW P  KINLEYPresident and Treasurer DES MOINESAUGUSTINE  LAWLORCAMBRIDGEJOHN W  LITTLECHILDCAMBRIDGEPHILIP  MACNEILLVP, CFO, Treasurer, Secretary ANNAPOLISBRIAN A  MARKISONDirector ANNAPOLISBRIAN A  MARKISONDirector ANNAPOLISBRIAN A  MARKISONDirector ANNAPOLISJoel  McClearyDirector ANNAPOLISJoel  McClearyDirector ANNAPOLISJoel  McClearyDirector ANNAPOLISMILLENNIUM MANAGEMENT, L.L.C.NEW YORKChristopher  MirabelliCAMBRIDGESayare  MitchelAnnapolisWAYNE  MORGESVP, Regulatory Affairs & Qual ANNAPOLISWAYNE  MORGESVP, Regulatory Affairs & Qual ANNAPOLISWAYNE  MORGESSVP, Reg. Affairs & Quality ANNAPOLISMPM Asset Management Investors 2004 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, LPBOSTONMPM BIOVENTURES III QP LPBOSTONAG  NOVARTISCH-4002, BASELNovartis Bioventures LtdHAMILTONJOHN  PAPPAJOHNChairman and Secretary DES MOINESJOHN  PAPPAJOHNDirector ANNAPOLISJOHN  PAPPAJOHNDirector ANNAPOLISJOHN  PAPPAJOHNDirector ANNAPOLISJOHN  PAPPAJOHNDES MOINESJOHN  PAPPAJOHNChairman and Secretary DES MOINESJOHN  PAPPAJOHNChairman and Secretary DES MOINESJOHN  PAPPAJOHNChairman and Secretary DES MOINESParadigm Venture Partners, L.P.GAITHERSBURGPRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.TULSAPRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.TULSAPRESCOTT GROUP CAPITAL MANAGEMENT LLC10% Owner TULSAKevin  PricePresident-PharmAthene UK Ltd BILLINGHAMKevin  PricePresident - PharmAthene UK,Ltd BILLINGHAMRedmont VAXN Capital Holdings, LLCGAITHERSBURGRedmont Venture Partners, Inc.GAITHERSBURGCharles A.  Reinhart IIIANNAPOLISCharles A.  Reinhart IIISVP, Chief Financial Officer ANNAPOLISCharles A.  Reinhart IIISVP, Chief Financial Officer ANNAPOLISERIC I  RICHMANDirector NEW YORKERIC I  RICHMANSee Remarks ANNAPOLISERIC I  RICHMANSee Remarks ANNAPOLISERIC I  RICHMANPresident and CEO ANNAPOLISValerie D  RiddleSVP, Medical Director ANNAPOLISM Scot  RobertsChief Scientific Officer GAITHERSBURGJeffrey W.  RungeDirector ANNAPOLISJeffrey W.  RungeDirector ANNAPOLISJeffrey W.  RungeDirector ANNAPOLISMITCHEL  SAYAREDirector CAMBRIDGEMITCHEL  SAYAREANNAPOLISKlaus  SchaferDirector GAITHERSBURGDERACE L  SCHAFFERDirector ROCHESTERDERACE L  SCHAFFERVice Chairman and CEO DES MOINESDERACE L  SCHAFFERVice Chairman and CEO DES MOINESDERACE L  SCHAFFERDirector ANNAPOLISDERACE L  SCHAFFERDirector ANNAPOLISDERACE L  SCHAFFERDES MOINESDERACE L  SCHAFFERDirector DES MOINESDERACE L  SCHAFFERVice Chairman and CEO DES MOINESWayne A  SchellhammerIRVINGNICHOLAS J  SIMON IIIBOSTONPeter Steven  StDirector NEW YORKPeter Steven  StDirector BOSTONPeter Steven  StDirector ANNAPOLISPeter Steven  StDirector ANNAPOLISMICHAEL  STEINMETZBOSTONSt. Peter  StevenAnnapolisSt. Peter  StevenAnnapolisSybil  TaskerChief Medical Officer GAITHERSBURGFuerst  ThomasAnnapolisRiddle  ValerieAnnapolisRiddle  ValerieAnnapolisMorges  WayneAnnapolisMorges  WayneAnnapolisHAROLD R  WERNERPrincetonHAROLD R  WERNERPRINCETONKURT  WHEELERBOSTONDAVID P  WRIGHTPresident and CEO ANNAPOLISPersons related to MPM BIOVENTURES III-QP L.P. - Pernix Sleep, Inc.NamePositionCityMichael D  AllenSVP, Sales and Marketing SAN DIEGOBA Venture Partners VI, LLCFOSTER CITYBAVP, L.P.10% Owner FOSTER CITYBAVP, L.P.10% Owner FOSTER CITYJAMES C  BLAIR10% Owner PRINCETONJAMES C  BLAIR10% Owner PRINCETONLOUIS C  BOCKDirector FOSTER CITYLOUIS C  BOCKFOSTER CITYLOUIS C  BOCKFOSTER CITYBoxer Asset Management Inc.NEW PROVIDENCEBoxer Asset Management Inc.NEW PROVIDENCEBoxer Capital, LLC DEL MARDorsey  BrianSolana BeachMark J  BrooksFOSTER CITYTerrell  CobbSAN DIEGOTerrell  CobbDirector SAN DIEGOTerrell  CobbDirector SAN DIEGOTerrell  CobbDirector SAN DIEGOTerrell  CobbDirector SAN DIEGOTerrell  CobbDirector SAN DIEGOTerrell  CobbDirector SOLANA BEACHKenneth M  CohenPresident and CEO SAN DIEGOKenneth M  CohenPresident and CEO SAN DIEGOHale  DavidSolana BeachMANAGEMENT CO /NY  DEERFIELDNEW YORKDeerfield Mgmt L.P.NEW YORKDeerfield Special Situations Fund, L.P.NEW YORKDeerfield Special Situations International Master Fund, L.P.NEW YORKASSOCIATES  DOMAINPRINCETONDomain Partners VI, L.P.10% Owner PRINCETONDomain Partners VI, L.P.10% Owner PRINCETONBrian  DorseyVP Product Development SAN DIEGOBrian  DorseySVP, Technical Operations SAN DIEGOBrian  DorseySVP, Technical Operations SAN DIEGOBrian  DorseySVP, Technical Operations SAN DIEGOBrian  DorseySVP, Technical Operations SAN DIEGOBrian  DorseySVP, Technical Operations SOLANA BEACHBRIAN H  DOVEY10% Owner PRINCETONBRIAN H  DOVEY10% Owner PRINCETONDP VI Associates, L.P.10% Owner PRINCETONSusan  DubeSenior VP, Corp and Bus Dev SAN DIEGOSusan  DubeSenior VP, Corp and Bus Dev SAN DIEGOMICHAEL L  EAGLEDirector SAN DIEGOMICHAEL L  EAGLEDirector SAN DIEGOMICHAEL L  EAGLEDirector SAN DIEGOMICHAEL L  EAGLEDirector SOLANA BEACHMICHAEL L  EAGLEDirector SAN DIEGOKURT VON  EMSTERDirector SAN DIEGOKURT VON  EMSTERDirector SOLANA BEACHKURT VON  EMSTERDirector SOUTH SAN FRANCISCOKURT VON  EMSTERBOSTONKURT VON  EMSTERDirector SAN DIEGOKURT VON  EMSTERDirector SOUTH SAN FRANCISCOKURT VON  EMSTERDirector SAN DIEGOKURT VON  EMSTERDirector SAN DIEGOMast  ErleSolana BeachLUKE  EVNIN10% Owner BOSTONJames E  FlynnNEW YORKANSBERT  GADICKEBOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONNICHOLAS  GALAKATOSBOSTONCAM L  GARNERDirector SAN DIEGOCAM L  GARNERDirector SAN DIEGOCAM L  GARNERDirector SAN DIEGOSCOTT L  GLENNDirector SAN DIEGOSCOTT L  GLENNDirector SAN DIEGOSCOTT L  GLENNDirector SAN DIEGODAVID F  HALEDirector CARLSBADDAVID F  HALEDirector SAN DIEGODAVID F  HALEDirector SAN DIEGODAVID F  HALEDirector SOLANA BEACHDAVID F  HALEDirector SAN DIEGODAVID F  HALEExecutive Chairman SAN DIEGODAVID F  HALEDirector SAN DIEGOFaheem  HasnainDirector SAN DIEGOFaheem  HasnainDirector SAN DIEGOFaheem  HasnainDirector SOLANA BEACHDENNIS  HENNERBOSTONDENNIS  HENNERBOSTONRaser  JeffreySolana BeachTreu  JessePrincetonPhilip  JochelsonSenior VP and Chief Medical SAN DIEGOPhilip  JochelsonSenior VP and Chief Medical SAN DIEGOROBERT LEWIS  JONESVP of Human Resources SAN DIEGOWheeler  KurtSolana Beachvon Emster  KurtSolana BeachJOSEPH  LEWISNEW PROVIDENCEJOSEPH  LEWISNEW PROVIDENCEJAMES J  LITALIENSVP Regulatory Affairs & QA SAN DIEGOERLE T  MASTDirector SAN DIEGOERLE T  MASTDirector SOLANA BEACHERLE T  MASTDirector SAN DIEGOERLE T  MASTDirector SAN DIEGOERLE T  MASTDirector SAN DIEGOOnaitis  MatthewSolana BeachMeg  McGilleyVP, CFO, Treasurer, Secretary SAN DIEGOMeg  McGilleyVP, CFO, Treasurer SAN DIEGOEagle  MichaelSolana BeachKATE  MITCHELLFOSTER CITYMONTREUX EQUITY MANAGEMENT II SBIC LLCMENLO PARKMONTREUX EQUITY MANAGEMENT II SBIC LLCMENLO PARKEquity Managment SBIC  Montreux IIIMENLO PARKEquity Managment SBIC  Montreux IIIMENLO PARKMONTREUX EQUITY PARTNERS II SBIC LPMENLO PARKMONTREUX EQUITY PARTNERS II SBIC LP10% Owner MENLO PARKMONTREUX EQUITY PARTNERS III SBIC L PMENLO PARKMONTREUX EQUITY PARTNERS III SBIC L PROBERT J  MORE10% Owner PRINCETONROBERT J  MORE10% Owner PRINCETONMPM Asset Management Investors 2005 BVIII LLCBOSTONMPM Asset Management Investors 2005 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, LPBOSTONMPM BIOVENTURES III QP LP10% Owner BOSTONMVA Investors, LLCDEL MARTran  NguyenVice President and CFO SOLANA BEACHTran  NguyenSVP and CFO SAN DIEGOTran  NguyenSVP and CFO SAN DIEGOTran  NguyenSVP and CFO SAN DIEGOTran  NguyenSVP and CFO SOLANA BEACHTran  NguyenSVP and CFO SOLANA BEACHRory  O'DriscollFOSTER CITYMatthew  OnaitisVice President, Legal Affairs SAN DIEGOMatthew  OnaitisVP, General Counsel SAN DIEGOMatthew  OnaitisSVP, General Counsel SAN DIEGOMatthew  OnaitisSVP, General Counsel SAN DIEGOMatthew  OnaitisSVP, General Counsel SAN DIEGOMatthew  OnaitisSVP, General Counsel SAN DIEGOMatthew  OnaitisSVP, General Counsel SOLANA BEACHMatthew  OnaitisSVP, General Counsel SOLANA BEACHHOWARD D  PALEFSKYMENLO PARKHOWARD D  PALEFSKYMENLO PARKHOWARD D  PALEFSKYMENLO PARKRichard W  PascoePresident and CEO SAN DIEGORichard W  PascoePresident and CEO SAN DIEGORichard W  PascoePresident and CEO SAN DIEGORichard W  PascoePresident and CEO SAN DIEGORichard W  PascoePresident and CEO SAN DIEGORichard W  PascoePresident and CEO SOLANA BEACHJeffrey  RaserSenior VP, Sales and Marketing SAN DIEGOJeffrey  RaserSenior VP, Sales and Marketing SAN DIEGOJeffrey  RaserSVP, Chief Commercial Officer SAN DIEGOJeffrey  RaserSVP, Chief Commercial Officer SAN DIEGOPascoe  RichardSolana BeachScale Venture Management I, LLCFOSTER CITYKATHLEEN K  SCHOEMAKER10% Owner PRINCETONKATHLEEN K  SCHOEMAKER10% Owner PRINCETONNICHOLAS J  SIMON IIIBOSTONNICHOLAS J  SIMON IIIBOSTONMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZBOSTONCobb  TerrellSolana BeachWiggans  ThomasSolana BeachJESSE I  TREUDirector PRINCETONJESSE I  TREUDirector PRINCETONDANIEL K  TURNER IIIMENLO PARKDANIEL K  TURNER IIIMENLO PARKDANIEL K  TURNER IIIDirector SAN DIEGODANIEL K  TURNER IIIDirector SAN DIEGODANIEL K  TURNER IIIDirector SAN DIEGONICOLE  VITULLO10% Owner PRINCETONNICOLE  VITULLO10% Owner PRINCETONKURT  WHEELERDirector SAN DIEGOKURT  WHEELERDirector SAN DIEGOKURT  WHEELERBOSTONKURT  WHEELERDirector BOSTONKURT  WHEELERDirector SAN DIEGOTHOMAS G  WIGGANSDirector SAN DIEGOTHOMAS G  WIGGANSDirector SAN DIEGOTHOMAS G  WIGGANSDirector SAN DIEGOTHOMAS G  WIGGANSDirector SAN DIEGOPersons related to MPM BIOVENTURES III-QP L.P. - EnteroMedics IncNamePositionCityAberdare GP II, L.L.C.10% Owner SAN FRANCISCOAberdare GP II, L.L.C.SAN FRANCISCOABERDARE II ANNEX FUND L P10% Owner SAN FRANCISCOABERDARE II ANNEX FUND L PSAN FRANCISCOAberdare Ventures II (Bermuda), L.P.SAN FRANCISCOAberdare Ventures II, L.P.10% Owner SAN FRANCISCOAberdare Ventures II, L.P.10% Owner SAN FRANCISCODonders  AdrianusSt PaulNaqeeb A.  AnsariSVP of Sales ST. PAULBAY CITY CAPITAL FUND IV CO INVESMENT FUND LPSAN FRANCISCOBAY CITY CAPITAL FUND IV CO INVESMENT FUND LPSAN FRANCISCOBAY CITY CAPITAL FUND IV CO INVESMENT FUND LPSAN FRANCISCOBay City Capital Fund IV, L.P.SAN FRANCISCOBay City Capital Fund IV, L.P.SAN FRANCISCOBay City Capital Fund IV, L.P.SAN FRANCISCOBay City Capital Fund IV, L.P.SAN FRANCISCOBAY CITY CAPITAL LLC10% Owner SAN FRANCISCOBAY CITY CAPITAL LLC10% Owner SAN FRANCISCOBAY CITY CAPITAL LLC10% Owner SAN FRANCISCOBay City Capital Management IV LLCSAN FRANCISCOBay City Capital Management IV LLCSAN FRANCISCOBay City Capital Management IV LLCSAN FRANCISCOGARY  BLACKFORDDirector EDEN PRAIRIEGriffin  BobbySt. PaulGriffin  BobbySt PaulMICHAEL D  BOICHMENLO PARKGoldfischer  CarlSt. PaulGoldfischer  CarlSan FranciscoHARVEY B  CASHMENLO PARKFriedman  CatherineSt PaulBRUCE A  CLEVELANDMENLO PARKGladney  DanSt. PaulPeter M.  DeLangeSVP, Ops & Bus Dev ST. PAULHarrison  DonaldSt PaulAdrianus  DondersSr VP of Research & Adv Dev ST. PAULDOUGLAS FAMILY TRUSTLARKSPURKEVIN  DOUGLAS10% Owner LARKSPURMichelle  DouglasLARKSPURChristopher B  EhrlichMENLO PARKKoskinas  EllenMenlo ParkRuss  FelkeySr VP-Clinical,Qual&RegAffair MINNEAPOLISCATHY  FRIEDMANDirector SANTA CLARACATHY  FRIEDMANDirector ST. PAULANSBERT  GADICKE10% Owner BOSTONNICHOLAS  GALAKATOSBOSTONBlackford  GarySt. PaulSander  GerberNEW YORKPHILIP T  GIANOSMENLO PARKDAN W  GLADNEYChrm, Pres & CEO NEW BRIGHTONCARL  GOLDFISCHERDirector SAN FRANCISCOCARL  GOLDFISCHERDirector NEW YORKCARL  GOLDFISCHERDirector SAN FRANCISCOCARL  GOLDFISCHERDirector SAN FRANCISCOLinda S  GraisMENLO PARKLea  GregSt PaulBOBBY IVAN  GRIFFINDirector GOLDEN VALLEYBOBBY IVAN  GRIFFINDirector ST. PAULBradford C  HancockST. PAULDONALD C  HARRISONDirector ST. PAULDENNIS  HENNERBOSTONHFR MASTER TRUSTSHAMILTON HM 11HFR MASTER TRUSTSHAMILTON, HM 11Paul F.  HickeySVP of Mktg & Reimb ST. PAULW Stephen  HolmesMENLO PARKHudson Bay Capital Management, L.P.10% Owner NEW YORKHudson Bay Fund LPNEW YORKHudson Bay Fund LPNEW YORKHudson Bay Overseas Fund Ltd.NEW YORKInterWest Management Partners IX, LLC10% Owner MENLO PARKInterWest Partners IX, LP10% Owner MENLO PARKJAMES & JEAN DOUGLAS IRREVOCABLE DESCENDANTS TRUSTLARKSPURAnthony P.  JanszDirector ST. PAULTremmel  JonSt PaulTremmel  JonSt. PaulKGD 2010 Annuity Trust VILARKSPURKGD 2010 Annuity Trust VILARKSPURNina S  KjellsonMENLO PARKGilbert H  KlimanMENLO PARKPAUL H  KLINGENSTEINDirector PALO ALTOPAUL H  KLINGENSTEINDirector SAN FRANCISCOPAUL H  KLINGENSTEINDirector SAN FRANCISCOPAUL H  KLINGENSTEINDirector SAN FRANCISCOMARK B  KNUDSONDirector ST. PAULGARY S  KOHLERMINNEAPOLISEllen E  KoskinasDirector MENLO PARKEllen E  KoskinasDirector MENLO PARKGREGORY S  LEACFO and CCO ROCHESTERGREGORY S  LEASVP , CFO and COO MINNEAPOLISMcDougal  LoriSt. PaulEvnin  LukeBostonKnudson  MarkSt PaulMARXE AUSTIN W & GREENHOUSE DAVID M10% Owner NEW YORKLori Courtney  McDougalDirector ST. PAULMMD 2010 Annuity Trust VILARKSPURMMD 2010 Annuity Trust VILARKSPURMPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, LPBOSTONMPM BIOVENTURES III QP LP10% Owner BOSTONAnsari  NaqeebSt. PaulH Ronald  NashMENLO PARKKHALED  NASRMENLO PARKTeti  NicholasSt PaulTeti, Jr.  NicholasSt. PaulRajesh  NihalaniChief Technology Officer ST. PAULARNOLD L  ORONSKYMENLO PARKPandora Select Partners, L.P.MINNEAPOLISHickey  PaulSt. PaulKlingenstein  PaulSan FranciscoDouglas A  PepperMENLO PARKDeLange  PeterSt. PaulNihalani  RajeshSt. PaulThomas L  RoschMENLO PARKYoungstrom  ScottSt. PaulScott A  ShikoraEVP & Chief Medical Officer ST. PAULNICHOLAS J  SIMON IIIBOSTONMICHAEL  STEINMETZBOSTONMICHAEL B  SWEENEYMENLO PARKNICHOLAS  TETIDirector SANTA BARBARANICHOLAS  TETIDirector MINNEAPOLISJon T  TremmelDirector ST. PAULJon T  TremmelDirector ST. PAULKatherine S.  TwedenVP - Clinical and Regulatory ST. PAULVictor A  WesterlindMENLO PARKKURT  WHEELERBOSTONWHITEBOX ADVISORS LLC10% Owner MINNEAPOLISWhitebox L/S Equity Partners LPMINNEAPOLISWhitebox Multi-Strategy Partners LPMINNEAPOLISWhitebox Small Cap Long Short Equity Advisors, LLCMINNEAPOLISWhitebox Small Cap Long Short Equity Partners LPMINNEAPOLISSCOTT P  YOUNGSTROMCFO & CCO NEW BRIGHTONPersons related to MPM BIOVENTURES III-QP L.P. - ARYx Therapeutics, Inc.NamePositionCityRobert J  AdelmanDirector FREMONTRobert J  AdelmanDirector FREMONTJason  BarkerSr.Dir.& Principal Acctg. Off. FREMONTM JAMES  BARRETTBALTIMOREM JAMES  BARRETTTIMONIUMPETER J  BARRISBALTIMOREPETER J  BARRISTIMONIUMFOREST  BASKETTBALTIMOREFOREST  BASKETT10% Owner TIMONIUMDAVID W  BEIERDirector FREMONTDaniel  CanafaxV.P.  & CDO FREMONTCanafax  DanielFremontBeier  DavidFremontNagler  DavidFremontRYAN D  DRANTBALTIMORERYAN D  DRANT10% Owner TIMONIUMPascal  DruzgalaSr. V.P. & Chief Scien.Off. FREMONTLars  EkmanDirector FREMONTLars  EkmanDirector FREMONTANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONPAUL  GODDARDChairman & CEO FREMONTGrowth Equity Opportunities Fund, LLCBALTIMOREGrowth Equity Opportunities Fund, LLC10% Owner TIMONIUMDENNIS  HENNERBOSTONRosenman  HermFremontRosenman  HermnFremontSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORK NYVarian  JohnFremontLeonard  KeithFremontPATRICK J  KERINSBALTIMOREPATRICK J  KERINS10% Owner TIMONIUMKRISHNA KITTU  KOLLURIBALTIMOREKRISHNA KITTU  KOLLURI10% Owner TIMONIUMC RICHARD  KRAMLICHBALTIMOREC RICHARD  KRAMLICHTIMONIUMEkman  LarsFremontKeith R  LeonardDirector FREMONTKeith R  LeonardDirector FREMONTCHARLES M  LINEHANBALTIMOREPeter G  MilnerPres., Research & Dev. FREMONTMPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, LPBOSTONMPM BIOVENTURES III QP LP10% Owner BOSTONMPM BioVentures Strategic Fund LPBOSTONDavid  NaglerV.P.,Corp. Affairs & Sect. FREMONTNEA 12 GP, LLCBALTIMORENEA 12 GP, LLCTIMONIUMPartners 12, Limited Partnership  NEABALTIMOREPartners 12, Limited Partnership  NEATIMONIUMEnterprise Associates 12, Limited Partnership  NewBALTIMOREEnterprise Associates 12, Limited Partnership  NewTIMONIUMCHARLES W  NEWHALL IIIBALTIMORECHARLES W  NEWHALL IIITIMONIUMSimon  NickFremontNomura Phase4 Ventures LPLONDONNomura Phase4 Ventures LTD10% Owner LONDONORBIMED ADVISORS LLC10% Owner NEW YORKDruzgala  PascalFremontDruzgala  PascalFremontGoddard  PaulFremontSekhri  PaulFremontMARK W  PERRYBALTIMOREMARK W  PERRYTIMONIUMMilner  PeterFremontHERM  ROSENMANDirector FREMONTHERM  ROSENMANDirector FREMONTSCOTT D  SANDELLBALTIMORESCOTT D  SANDELLTIMONIUMPAUL J  SEKHRIDirector FREMONTNICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector FREMONTMICHAEL  STEINMETZBOSTONEUGENE A  TRAINOR IIIBALTIMOREJohn  VarianCOO & CFO FREMONTKURT  WHEELERBOSTONPersons related to MPM BIOVENTURES III-QP L.P. - Radius Health, Inc.NamePositionCityAuerbach  AlanCambridgeGadicke  AnsbertCambridgeALAN H  AUERBACHDirector LOS ANGELESALAN H  AUERBACHDirector CAMBRIDGEALAN H  AUERBACHDirector WALTHAMHarvey  B.CambridgeBIOTECH AG  BBSCHAFFHAUSENBIOTECH AG  BBSCHAFFHAUSEN, SWITZERLANDBIOTECH AG  BBSCHAFFHAUSENGROWTH N V  BIOTECH10% Owner CURACOGROWTH N V  BIOTECH10% Owner CURACAOLOUIS MD  BRENNERChief Medical Officer CAMBRIDGEBROOKSIDE CAPITAL INVESTORS L PBOSTONBROOKSIDE CAPITAL MANAGEMENT LLC10% Owner BOSTONBROOKSIDE CAPITAL PARTNERS FUND LPBOSTONBROOKSIDE CAPITAL PARTNERS FUND LPBOSTONLyttle  C.CambridgeJose  CarmonaChief Financial Officer NEWTOWN SQUAREJAMES H  CAVANAUGHPRINCETONJAMES H  CAVANAUGHCAMBRIDGEWillard H  DereDirector THOUSAND OAKSWillard H  DereWALTHAMWillard H  DereDirector WALTHAMASHLEY L  DOMBKOWSKISOUTH SAN FRANCISCOMark  DurandCAMBRIDGEStoner  ElizabethCambridgeLUKE  EVNIN BOSTONLUKE  EVNIN10% Owner BOSTONLUKE  EVNINBOSTONF2 Bio Ventures GP Ltd.ROAD TOWN, TORTOLAF2 Bio Ventures GP Ltd.TORTOLAF2 Bio Ventures GP Ltd.ROAD TOWN, TORTOLAF2 Bio Ventures V L.P.ROAD TOWN, TORTOLAF2 Bio Ventures V L.P.TORTOLAF2 Bio Ventures V L.P.ROAD TOWN, TORTOLAF2 Bioscience GP Ltd.GEORGE TOWNF2 Bioscience III, L.P.10% Owner GEORGE TOWNF2 Bioscience IV GP Ltd.GEORGE TOWNF2 Bioscience IV GP Ltd.GEORGE TOWNF2 Bioscience IV L.P.10% Owner GEORGE TOWNF2 Bioscience IV L.P.10% Owner GEORGE TOWNF2 Bioscience VI L.P.GEORGE TOWNF2 Capital LtdGEORGE TOWNF2 Capital Ltd10% Owner TORTOLAF2 Capital LtdTORTOLAF2 Capital LtdTORTOLALorraine A.  FitzpatrickChief Medical Officer WALTHAMJONATHAN  FLEMINGDirector CAMBRIDGEJONATHAN  FLEMINGCAMBRIDGETodd  FoleyCAMBRIDGETodd  FoleyBOSTONMichael  FrankenCAMBRIDGECATHY  FRIEDMANDirector SANTA CLARAAndrew J.  FromkinCAMBRIDGEANSBERT  GADICKEDirector BOSTONANSBERT  GADICKEDirector WALTHAMANSBERT  GADICKEDirector BOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOS BOSTONNICHOLAS  GALAKATOS10% Owner BOSTONNICHOLAS  GALAKATOS10% Owner BOSTONJEAN PIERRE  GARNIERDirector HARTFORDHattersley  GaryCambridgeGlobeways Holdings LtdROAD TOWN, TORTOLAGlobeways Holdings LtdTORTOLAGlobeways Holdings LtdROAD TOWN, TORTOLAKurt  GravesDirector CAMBRIDGEKurt  GravesCAMBRIDGEKurt  GravesDirector CAMBRIDGEKurt  GravesDirector WALTHAMWilliam  GreeneSOUTH SAN FRANCISCOALAN G  HARRISChief Medical Officer CAMBRIDGEALAN G  HARRISChief Medical Officer WALTHAMBrian Nicholas  HarveySr. VP and CFO CAMBRIDGEBrian Nicholas  HarveySr VP & CFO, Sec. & Treasurer CAMBRIDGEBrian Nicholas  HarveySr. Vice President & CFO WALTHAMGary  HattersleyChief Scientific Officer CAMBRIDGEGary  HattersleySr. VP & Chief Scientific Off. CAMBRIDGEGary  HattersleyChief Scientific Officer WALTHAMBrent  Hatzis-SchochSr. VP, General Counsel WALTHAMHealthCare Partners VII, L.P.PRINCETONHealthCare Partners VII, L.P.CAMBRIDGEPrivate Equity Limited Partnership  HealthcareEDINBURGHHEALTHCARE VENTURES VII LPPRINCETONHEALTHCARE VENTURES VII LP10% Owner CAMBRIDGEDENNIS  HENNERSOUTH SAN FRANCISCODENNIS  HENNERBOSTONDENNIS  HENNERBOSTONJesper  HoilandPresident and CEO WALTHAMOwen  HughesDirector CAMBRIDGEOwen  HughesDirector WALTHAMPharma SAS  IpsenBOULOGNE BILLANCOURTS.A.  Ipsen,BOULOGNE BILLANCOURTFleming  JonathanCambridgeMorana  Jovan-EmbiricosDirector CAMBRIDGEMorana  Jovan-EmbiricosDirector CAMBRIDGEMorana  Jovan-EmbiricosDirector WALTHAMVAUGHN M  KAILIANVAUGHN M  KAILIANBOSTONVAUGHN M  KAILIANBOSTONGraves  KurtCambridgeAUGUSTINE  LAWLORCAMBRIDGEJOHN W  LITTLECHILDCAMBRIDGEO'Dea  LouisCambridgeCecil Richard  LyttlePresident and C.E.O. CAMBRIDGECecil Richard  LyttlePresident and CEO CAMBRIDGECecil Richard  LyttleCAMBRIDGEMuenchbach  MartinCambridgeChristopher  MirabelliCAMBRIDGEMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM Bio IV NVS Strategic Fund LPBOSTONMPM Bio IV NVS Strategic Fund LPBOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLC BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III QP LPBOSTONMPM BioVentures IV GP LLCBOSTONMPM BioVentures IV GP LLCBOSTONMPM BioVentures IV LLC10% Owner BOSTONMPM BioVentures IV LLC10% Owner BOSTONMartin  MuenchbachDirector SAN DIEGOMartin  MuenchbachDirector CAMBRIDGEMartin  MuenchbachDirector CAMBRIDGEMartin  MuenchbachDirector CAMBRIDGEMartin  MuenchbachDirector WALTHAMBioscience Clinical Development VII A/S  NordicHERLEVBioscience Clinical Development VII A/S  Nordic10% Owner HERLEVLouis  O'DeaCAMBRIDGEKatherine  PriestleyGEORGE TOWNKatherine  PriestleyLONDONKatherine  PriestleyLONDONKatherine  PriestleyLONDONDinesh  PurandareSVP, Head of Global Oncology WALTHAMAnthony  RosenbergDirector CAMBRIDGEDebasish  RoychowdhuryDirector WALTHAMJames Paul  ScopaS. SAN FRANCISCOJames Paul  ScopaSOUTH SAN FRANCISCONICHOLAS J  SIMON IIISOUTH SAN FRANCISCONICHOLAS J  SIMON IIIBOSTONNICHOLAS J  SIMON IIIBOSTONDavid P.  SnowChief Commercial Officer WALTHAMPeter Steven  StBOSTONPeter Steven  StBOSTONMICHAEL  STEINMETZSAN DIEGOMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZBOSTONElizabeth  StonerDirector BOSTONElizabeth  StonerBOSTONElizabeth  StonerDirector WALTHAMVort John  VanderBOSTONVort John  VanderBOSTONVort John  VanderBOSTONRob  WardPresident & CEO PALO ALTORobert  WardPresident & CEO CAMBRIDGERobert  WardPresident & CEO CAMBRIDGERobert  WardPresident & Chief Exec Officer WALTHAMWELLCOME TRUST LTDLONDON NW1 2BEWELLCOME TRUST LTD10% Owner LONDONWELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST10% Owner LONDONHAROLD R  WERNERPRINCETONHAROLD R  WERNERCAMBRIDGEKURT  WHEELERBOSTONKURT  WHEELERBOSTONKURT  WHEELERBOSTONGregory C.  WilliamsChief Development Officer CAMBRIDGEGregory C.  WilliamsChief Development Officer CAMBRIDGEGregory C.  WilliamsChief Development Officer WALTHAMMICHAEL S  WYZGAChief Executive Officer CAMBRIDGEJohn  YatesCAMBRIDGEJohn  YatesChief Medical Officer CAMBRIDGE
Potentially same personNameCityCountryMPM BIOVENTURES III-QP L.P.BOSTONMAMPM BIOVENTURES III-QP L.P.BOSTONMA












 









403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.






MPM BIOVENTURES III QP LP - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











MPM BIOVENTURES III QP LP
Check out list of companies and businesses related to MPM BIOVENTURES III QP LP. Find out MPM BIOVENTURES III QP LP address and contact details. View other people related to MPM BIOVENTURES III QP LP - coworkers, colleagues, companions, etc.
Address:   

C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON 02199 MA




Companies related to MPM BIOVENTURES III QP LP
CIKCompany NamePositionCompany Address0001034842RIGEL PHARMACEUTICALS INC10% Owner 1180 VETERANS BOULEVARD  SOUTH SAN FRANCISCO 940800001053221METABASIS THERAPEUTICS INC9390 TOWNE CENTRE DRIVE  SAN DIEGO 921210001138812COTHERIX INC10% Owner 5000 SHORELINE COURT SUITE 101 SOUTH SAN FRANCISCO 940800001145404CORNERSTONE THERAPEUTICS INC10% Owner 1255 CRESCENT GREEN DRIVE SUITE 250 CARY 275180001173657BARRIER THERAPEUTICS INC10% Owner 600 COLLEGE ROAD EAST SUITE 3200 PRINCETON 085400001262175TERCICA INC2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE 940050001428522Radius Health, Inc.ATTN CHIEF FINANCIAL OFFICER 950 WINTER STREET WALTHAM 02451




MPM BIOVENTURES III QP LP on the Web
Persons related to MPM BIOVENTURES III QP LP - RIGEL PHARMACEUTICALS INCNamePositionCityALTA BIOPHARMA MANAGEMENT II LLCSAN FRANCISCOALTA BIOPHARMA PARTNERS II LPSAN FRANCISCOALTA CALIFORNIA MANAGEMENT PARTNERS LPSAN FRANCISCOALTA CALIFORNIA PARTNERS LPSAN FRANCISCOALTA EMBARCADERO BIOPHARMA PARTNERS II LLCSAN FRANCISCOALTA EMBARCADERO PARTNERS LLCSAN FRANCISCOPARTNERS  ALTASAN FRANCISCOALTA PARTNERS II INC10% Owner SAN FRANCISCOBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOBVF INC/ILCHICAGOBVF INC/ILCHICAGOBVF INC/ILCHICAGOBVF INVESTMENTS LLCCHICAGOBVF INVESTMENTS LLCCHICAGOBVF INVESTMENTS LLCCHICAGOBVF PARTNERS L P/IL10% Owner CHICAGOBVF PARTNERS L P/IL10% Owner CHICAGOBVF PARTNERS L P/ILCHICAGOFARAH  CHAMPSISAN FRANCISCOROBIN D G  COOPERSr. V.P. Pharmaceutical Scs. SOUTH SAN FRANCISCOROBIN D G  COOPERSr. V.P. Pharmaceutical Scs. SOUTH SAN FRANCISCODEERFIELD CAPITAL LPNEW YORKDEERFIELD INTERNATIONAL LTDTORTOLAMANAGEMENT CO /NY  DEERFIELDNEW YORKDEERFIELD PARTNERS, LPNEW YORKDeerfield Special Situations Fund International LTDROAD TOWN, TORTOLADeerfield Special Situations Fund, L.P.NEW YORKJEAN  DELEAGEDirector SOUTH SAN FRANCISCOJEAN  DELEAGEDirector SAN FRANCISCOJEAN  DELEAGEDirector SAN FRANCISCOAnne-Marie  DuliegeChief Medical Officer PALO ALTOKURT VON  EMSTERBOSTONLUKE  EVNIN10% Owner BOSTONLUKE  EVNINBOSTONFHM IV LLCSEATTLEFHM IV LPSEATTLEJames E  Flynn10% Owner NEW YORKALAN D  FRAZIERDirector SEATTLEALAN D  FRAZIERDirector SEATTLEALAN D  FRAZIERDirector SEATTLEALAN D  FRAZIERDirector SEATTLEALAN D  FRAZIERDirector SEATTLEFRAZIER HEALTHCARE IV LP10% Owner SEATTLEANSBERT  GADICKE10% Owner BOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOS10% Owner BOSTONNICHOLAS  GALAKATOSBOSTONBradford S  GoodwinDirector SOUTH SAN FRANCISCOBradford S  GoodwinDirector SOUTH SAN FRANCISCOBradford S  GoodwinDirector SOUTH SAN FRANCISCOJAMES M  GOWERCEO & Board Chairman SOUTH SAN FRANCISCOJAMES M  GOWERCEO & Board Chairman SOUTH SAN FRANCISCOELLIOT B  GROSSBARDEVP, CMO SOUTH SAN FRANCISCOELLIOT B  GROSSBARDSr. VP Medical Development SOUTH SAN FRANCISCOElliott B  GrossbardEVP, CMO SOUTH SAN FRANCISCOGARRETT  GRUENERSAN FRANCISCODENNIS  HENNERDirector BOSTONINVESTMENT 10 LLCCHICAGOKeith  KatkinDirector SAN DIEGOMARK N  LAMPERTSAN FRANCISCOMARK N  LAMPERTSAN FRANCISCOMARK N  LAMPERTCHICAGOJoseph  LasagaVP Bus. Dev.& Alliance Mgmt. SOUTH SAN FRANCISCOROBERT  LIPTAKBOSTONGARY A  LYONSDirector PALO ALTOGARY A  LYONSDirector SOUTH SAN FRANCISCOGARY A  LYONSDirector SOUTH SAN FRANCISCOALIX  MARDUELSAN FRANCISCOEsteban  MasudaSr. VP Research SOUTH SAN FRANCISCOEldon C.  Mayer IIIEVP & Chief Commercial Officer SOUTH SAN FRANCISCORyan D  MaynardEVP & CFO SOUTH SAN FRANCISCORyan D  MaynardEVP & CFO SOUTH SAN FRANCISCOWALTER H  MOOSDirector SAN DIEGOWALTER H  MOOSDirector OAKLANDWALTER H  MOOSDirector MENLO PARKWALTER H  MOOSDirector SOUTH SAN FRANCISCOMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM BIOEQUITIES FUND GMBH & CO KGBOSTONMPM BIOEQUITIES GP LLCBOSTONMPM BIOEQUITIES GP LPBOSTONMPM BIOEQUITIES MASTER FUND LP10% Owner BOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONGUY P  NOHRASAN FRANCISCODONALD G  PAYANEVP, Pres. Discovery&Research SOUTH SAN FRANCISCODONALD G  PAYANEVP, Pres. Discovery&Research SOUTH SAN FRANCISCODONALD G  PAYANEVP, Pres. Discovery&Research SOUTH SAN FRANCISCOHOLLINGS  RENTONDirector SOUTH SAN FRANCISCOHOLLINGS  RENTONDirector RICHMONDHOLLINGS  RENTONDirector EMERYVILLEHOLLINGS  RENTONDirector SOUTH SAN FRANCISCOPETER S  RINGROSEDirector SOUTH SAN FRANCISCOPETER S  RINGROSEDirector SOUTH SAN FRANCISCORAUL R  RODRIGUEZCEO, President SOUTH SAN FRANCISCORAUL R  RODRIGUEZCEO, President SOUTH SAN FRANCISCOSTEPHEN A  SHERWINDirector SOUTH SAN FRANCISCOSTEPHEN A  SHERWINDirector SOUTH SAN FRANCISCOSTEPHEN A  SHERWINDirector FOSTER CITYSTEPHEN A  SHERWINDirector SOUTH SAN FRANCISCOSTEPHEN A  SHERWINDirector SOUTH SAN FRANCISCONICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector SAN FRANCISCOMICHAEL  STEINMETZ10% Owner BOSTONMICHAEL  STEINMETZBOSTONDOLLY  VANCEEVP Corp. Affairs, G.C., Sect. SOUTH SAN FRANCISCODOLLY  VANCEEVP Corp. Affairs, G.C., Sect. SOUTH SAN FRANCISCOJAMES H  WELCHCFO, VP & Secretary SOUTH SAN FRANCISCOJAMES H  WELCHCFO, VP & Secretary SOUTH SAN FRANCISCOKURT  WHEELERBOSTONPersons related to MPM BIOVENTURES III QP LP - METABASIS THERAPEUTICS INCNamePositionCityEdgardo  Baracchini JrSAN DIEGOEdgardo  Baracchini JrSenior VP, Bus. Development SAN DIEGOEdgardo  Baracchini JrSr. VP of Business Development LA JOLLAEdgardo  Baracchini JrSr. VP, Business Development LA JOLLAJohn W  BeckSAN DIEGOJohn W  BeckSenior VP, Finance & CFO SAN DIEGOJohn W  BeckChief Financial Officer LA JOLLAJohn W  BeckSr. VP, Finance & CFO LA JOLLAStephen C  BowsherMENLO PARKStephen C  BowsherMENLO PARKDANIEL D  BURGESSDirector SAN DIEGODANIEL D  BURGESSDirector SAN DIEGODANIEL D  BURGESSDirector LA JOLLADANIEL D  BURGESSDirector LA JOLLAHARVEY B  CASH10% Owner DALLASHARVEY B  CASHMENLO PARKHARVEY B  CASHMENLO PARKHARVEY B  CASHMENLO PARKSUISSE/  CREDIT10% Owner NEW YORK NY 10010SUISSE/  CREDITNEW YORK NY 10010SUISSE/  CREDIT10% Owner NEW YORK NY 10010SUISSE/  CREDIT10% Owner NEW YORK NY 10010SUISSE FIRST BOSTON/  CREDIT10% Owner NEW YORKMark D  ErionSAN DIEGOMark D  ErionChief Executive Officer LA JOLLALUKE  EVNINDirector BOSTONLUKE  EVNINDirector LA JOLLALUKE  EVNINDirector LA JOLLALUKE  EVNINDirector BOSTONHoward  FoytVice President LA JOLLAHoward  FoytVP of Clinical Development LA JOLLAWayne  FrostVP of Regulatory Affairs & QA LA JOLLAANSBERT  GADICKEBOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONNICHOLAS  GALAKATOSBOSTONPHILIP T  GIANOSMENLO PARKPHILIP T  GIANOSMENLO PARKPHILIP T  GIANOSMENLO PARKHeinz W  GschwendDirector SANTA ROSAHeinz W  GschwendDirector SAN DIEGOHeinz W  GschwendDirector LA JOLLABarry  GumbinerVP Clinical Development & CMO LA JOLLADAVID F  HALEDirector CARLSBADDAVID F  HALEDirector LA JOLLADAVID F  HALEDirector LA JOLLAW SCOTT  HEDRICKMENLO PARKW SCOTT  HEDRICKMENLO PARKW SCOTT  HEDRICKMENLO PARKW Stephen  HolmesMENLO PARKW Stephen  HolmesMENLO PARKW Stephen  HolmesMENLO PARKInterWest Investors VII, LPMENLO PARKInterWest Investors VII, LPMENLO PARKInterWest Investors VII, LPMENLO PARKINTERWEST MANAGEMENT PARTNERS VII LLCMENLO PARKINTERWEST MANAGEMENT PARTNERS VII LLCMENLO PARKINTERWEST MANAGEMENT PARTNERS VII LLCMENLO PARKINTERWEST PARTNERS VII L P10% Owner MENLO PARKINTERWEST PARTNERS VII L P10% Owner MENLO PARKINTERWEST PARTNERS VII L P10% Owner MENLO PARKGilbert H  KlimanMENLO PARKGilbert H  KlimanMENLO PARKGilbert H  KlimanMENLO PARKPaul K  LaikindSAN DIEGOPaul K  LaikindDirector LA JOLLAPaul K  LaikindPresident, CEO & Secretary LA JOLLATrisha  MillicanPrincipal Accounting Officer LA JOLLAMPM ASSET MANAGEMENT II LLCBOSTONMPM ASSET MANAGEMENT II LLCBOSTONMPM ASSET MANAGEMENT II LPBOSTONMPM ASSET MANAGEMENT II LPBOSTONMPM ASSET MANAGEMENT INVESTORS 2000B LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2000B LLCBOSTONMPM BIOVENTURES GMBH & CO PARALLEL BETEILIGUNGS KGBOSTONMPM BIOVENTURES II GMBH & CO PARALLEL BETEILIGUNGS KGBOSTONMPM BIOVENTURES II LPBOSTONMPM BIOVENTURES II LPBOSTONMPM BIOVENTURES II QP LP10% Owner BOSTONMPM BIOVENTURES II QP LP10% Owner BOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONTran  NguyenVP and CFO LA JOLLAARNOLD L  ORONSKYDirector LA JOLLAARNOLD L  ORONSKYDirector LA JOLLAARNOLD L  ORONSKYDirector MENLO PARKARNOLD L  ORONSKYDirector MENLO PARKARNOLD L  ORONSKYDirector MENLO PARKWILLIAM R  ROHNDirector LA JOLLAWILLIAM R  ROHNDirector LA JOLLAWILLIAM R  ROHNDirector SAN DIEGOWILLIAM R  ROHNDirector SAN DIEGOThomas L  RoschMENLO PARKThomas L  RoschMENLO PARKThomas L  RoschMENLO PARKGeorge  SchreinerDirector LA JOLLASICOR INC10% Owner IRVINEMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZBOSTONElizabeth  StonerDirector BOSTONKURT  WHEELERBOSTONKURT  WHEELERBOSTONPersons related to MPM BIOVENTURES III QP LP - COTHERIX INCNamePositionCityALTA BIOPHARMA MANAGEMENT III LLCSAN FRANCISCOALTA BIOPHARMA MANAGEMENT III LLCSAN FRANCISCOALTA BIOPHARMA MANAGEMENT III LLCSAN FRANCISCOALTA  BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGSAN FRANCISCOALTA  BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGSAN FRANCISCOALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGSAN FRANCISCOALTA BIOPHARMA PARTNERS III LPSAN FRANCISCOALTA BIOPHARMA PARTNERS III LP10% Owner SAN FRANCISCOALTA BIOPHARMA PARTNERS III LP SAN FRANCISCOALTA CALIFORNIA MANAGEMENT PARTNERS III LLCSAN FRANCISCOALTA CALIFORNIA MANAGEMENT PARTNERS III LLCSAN FRANCISCOALTA CALIFORNIA MANAGEMENT PARTNERS III LLCSAN FRANCISCOALTA CALIFORNIA PARTNERS III LPSAN FRANCISCOALTA CALIFORNIA PARTNERS III LPSAN FRANCISCOALTA CALIFORNIA PARTNERS III LPSAN FRANCISCOALTA EMBARCADERO BIOPHARMA PARTNERS III LLCSAN FRANCISCOALTA EMBARCADERO BIOPHARMA PARTNERS III LLCSAN FRANCISCOALTA EMBARCADERO BIOPHARMA PARTNERS III LLCSAN FRANCISCOALTA EMBARCADERO PARTNERS III LLCSAN FRANCISCOALTA EMBARCADERO PARTNERS III LLCSAN FRANCISCOALTA EMBARCADERO PARTNERS III LLCSAN FRANCISCOALTA EMBARCADERO PARTNERS III LLCSAN FRANCISCOALTA PARTNERS II INC10% Owner SAN FRANCISCOALTA PARTNERS II INCSAN FRANCISCOALTA PARTNERS II INCSAN FRANCISCOAlta Partners III, Inc.SAN FRANCISCOAlta Partners III, Inc.SAN FRANCISCOAlain  AzanSAN FRANCISCOFARAH  CHAMPSISAN FRANCISCOFARAH  CHAMPSISAN FRANCISCOFARAH  CHAMPSISAN FRANCISCOROBERT  CHESSDirector SOUTH SAN FRANCISCOROBERT  CHESSDirector SOUTH SAN FRANCISCOROBERT  CHESSDirector BRISBANEJEAN  DELEAGESAN FRANCISCOJEAN  DELEAGESAN FRANCISCOJEAN  DELEAGESAN FRANCISCOKlara  DickinsonSOUTH SAN FRANCISCOKlara  DickinsonVP, Regulatory Affairs SOUTH SAN FRANCISCOKlara  DickinsonVP, Regulatory Affairs BRISBANELUKE  EVNIN10% Owner BOSTONThomas  FeldmanChief Business Officer SOUTH SAN FRANCISCOThomas  FeldmanPres. and Chief Bus. Officer SOUTH SAN FRANCISCOThomas  FeldmanPresident / CBO BRISBANEANSBERT  GADICKEBOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONNICHOLAS  GALAKATOSBOSTONBradford S  GoodwinDirector SOUTH SAN FRANCISCOBradford S  GoodwinDirector SOUTH SAN FRANCISCOBradford S  GoodwinDirector BRISBANEBradford S  GoodwinDirector BRISBANE,Smith Christine  GrayExecutive VP, CFO, Secretary SOUTH SAN FRANCISCOSmith Christine  GrayEVP, Chief Financial Officer SOUTH SAN FRANCISCOSmith Christine  GrayExecutive VP, CFO & Secretary BRISBANEGARRETT  GRUENERSAN FRANCISCOGARRETT  GRUENERSAN FRANCISCOGARRETT  GRUENERSAN FRANCISCODAVID W  GRYSKADirector SOUTH SAN FRANCISCODAVID W  GRYSKADirector BRISBANEJAMES  HEALYDirector SAN FRANCISCOJAMES  HEALYDirector SAN FRANCISCODENNIS  HENNERBOSTONDENNIS  HENNERBOSTONEDWARD  HURWITZSAN FRANCISCOEDWARD  HURWITZSAN FRANCISCODANIEL  JANNEYDirector SAN FRANCISCODANIEL  JANNEYDirector SAN FRANCISCODANIEL  JANNEYDirector SOUTH SAN FRANCISCODANIEL  JANNEYDirector SAN FRANCISCODANIEL  JANNEYDirector BRISBANEAbhay  JoshiEVP, Chief Technical Officer SOUTH SAN FRANCISCOAbhay  JoshiEVP, Chief Technical Officer BRISBANEGeorge W  MahaffeySOUTH SAN FRANCISCOGeorge W  MahaffeySVP, Sales and Marketing SOUTH SAN FRANCISCOGeorge W  MahaffeySenior VP, Sales and Marketing BRISBANEALIX  MARDUELSAN FRANCISCOALIX  MARDUELSAN FRANCISCOALIX  MARDUELSAN FRANCISCORobert S  MichitarianSOUTH SAN FRANCISCORobert S  MichitarianVP and Gen. Counsel SOUTH SAN FRANCISCOMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONMPM BIOVENTURES III PARALLEL FUND, LPBOSTONGUY P  NOHRASAN FRANCISCOGUY P  NOHRASAN FRANCISCOGUY P  NOHRASAN FRANCISCOEDWARD  PENHOETSAN FRANCISCOEDWARD  PENHOETSAN FRANCISCOJAMES E  PENNINGTONSOUTH SAN FRANCSICOJAMES E  PENNINGTONEVP, Chief Medical Officer SOUTH SAN FRANCSICOJAMES E  PENNINGTONEVP, Chief Medical Officer SOUTH SAN FRANCISCOJAMES E  PENNINGTONEVP/Chief Medical Officer BRISBANEMICHAEL  POWELLSAN FRANCISCOHoward B  RosenDirector SOUTH SAN FRANCISCODonald J  SantelChief Executive Officer SOUTH SAN FRANCISCODonald J  SantelChief Executive Officer SOUTH SAN FRANCISCODonald J  SantelChief Executive Officer BRISBANENICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector BOSTONSofinnova Management V LLCSAN FRANCISCOSOFINNOVA VENTURE AFFILIATES V LPSAN FRANCISCOSOFINNOVA VENTURE PARTNERS V LPSAN FRANCISCOSOFINNOVA VENTURE PRINCIPALS V LPSAN FRANCISCOMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZBOSTONKURT  WHEELERBOSTONKURT  WHEELERBOSTONPersons related to MPM BIOVENTURES III QP LP - CORNERSTONE THERAPEUTICS INCNamePositionCityAdvanced Technology Ventures VI, L.P.WALTHAMAdvanced Technology Ventures VI, L.P.WALTHAMAdvanced Technology Ventures VI, L.P.WALTHAMAdvanced Technology Ventures VII(B), L.P.WALTHAMAdvanced Technology Ventures VII(B), L.P.WALTHAMAdvanced Technology Ventures VII(B), L.P.WALTHAMAdvanced Technology Ventures VII(C), L.P.WALTHAMAdvanced Technology Ventures VII(C), L.P.WALTHAMAdvanced Technology Ventures VII(C), L.P.WALTHAMADVANCED TECHNOLOGY VENTURES VII LPWALTHAMADVANCED TECHNOLOGY VENTURES VII LP10% Owner WALTHAMERIC  AGUIARCAMBRIDGEROBERTS  ALANCARYPOWELL  ANDREWCARYFAILLA  ANTONCARYATV Alliance 2003, L.P.WALTHAMATV Alliance 2003, L.P.WALTHAMATV Alliance Associates, L.L.C.WALTHAMATV Associates VI, L.L.C.WALTHAMATV Associates VI, L.L.C.WALTHAMATV Associates VII, L.L.C.WALTHAMATV Associates VII, L.L.C.WALTHAMATV Entrepreneurs VI, L.P.WALTHAMATV Entrepreneurs VI, L.P.WALTHAMATV Entrepreneurs VI, L.P.WALTHAMATV Entrepreneurs VII, L.P.WALTHAMATV Entrepreneurs VII, L.P.WALTHAMATV Entrepreneurs VII, L.P.WALTHAMChenyqua Michele  BaldwinVice President Finance CARYCarolina Pharmaceuticals Holdings, Ltd.HAMILTONCarolina Pharmaceuticals Ltd.THE VALLEYJAMES H  CAVANAUGHPRINCETONAlessandro  ChiesiPARMAAlessandro  ChiesiDirector PARMAFarmaceutici SpA  Chiesi10% Owner PARMAMaria Paola  ChiesiPARMAChiesi U.S. CorpPARMACODEANNE  CHRISTOPHERCARYCHRISTOPHER GEORGE  CODEANNECARYCHRISTOPHER GEORGE  CODEANNEDirector CARYCraig A  CollardPresident and CEO CARYCraig A  CollardChief Executive Officer CARYCornerstone Biopharma Holdings, Ltd.10% Owner CARYCOLLARD  CRAIGCARYWILLIAM  CROUSEPRINCETONBrian  DicksonChief Medical Officer CARYBrian  DicksonChief Medical Officer CARYIra  DuartePrincipal Accounting Officer CARYIra  DuartePrincipal Accounting Officer CARYRICHARD W  DUGANDirector LEXINGTONMichael David  EnrightDirector CARYMichael David  EnrightCARYGeorge Arthur  EsgroVice President Sales CARYLUKE  EVNIN BOSTONLUKE  EVNINBOSTONAnton Giorgio  FaillaPARMAAnton Giorgio  FaillaDirector PARMAFrederick  FinneganLEXINGTONFrederick  FinneganSVP of Sales and Marketing LEXINGTONJoshua B  FranklinVP, Strategy & Bus. Dev. CARYANSBERT  GADICKEBOSTONANSBERT  GADICKE BOSTONNICHOLAS  GALAKATOSDirector BOSTONNICHOLAS  GALAKATOSDirector BOSTONJean  GeorgeDirector LEXINGTONJean  GeorgeDirector WALTHAMJean  GeorgeDirector WALTHAMJean  GeorgeDirector WALTHAMJames A  HarperDirector CARYJames A  HarperDirector CARYHEALTHCARE PARTNERS  VI LPPRINCETONHEALTHCARE VENTURES VI LP10% Owner PRINCETONMichael Thomas  HeffernanDirector CARYMichael Thomas  HeffernanDirector CARYDana Charles  HiltSVP of Clinical Develop. & CMO LEXINGTONHARPER  JAMESCARYJOHNSON & JOHNSON10% Owner NEW BRUNSWICKJOHNSON & JOHNSON DEVELOPMENT CORP ET ALNEW BRUNSWICKThomas Patrick  KellyCFO & SVP Finance & Corp. Dev, LEXINGTONMCBEAN  KENNETHCARYSHAWVER  LAURACARYAUGUSTINE  LAWLORCAMBRIDGEJOHN W  LITTLECHILDCAMBRIDGESteven Michael  LutzExecutive Vice President CARYSteven Michael  LutzExecutive Vice President CARYAndreas  MaetzelVP, Clinical and Regulatory CARYAndreas  MaetzelVP, Clinical and Regulatory CARYVECCHIA  MARCOCARYKenneth  McBeanPresident CARYKenneth  McBeanPresident CARYALASTAIR STUART  MCEWANDirector CARYALASTAIR STUART  MCEWANCFO and Treasurer CARYMedImmune Ventures, Inc.10% Owner GAITHERSBURGENRIGHT  MICHAELCARYHEFFERNAN  MICHAELCARYCHRISTOPHER  MIRAELLICAMBRIDGECHRISTOPHER  MIRAELLIPRINCETONCHRISTOPHER  MIRAELLIDirector CAMBRIDGEVincent T.  MorgusEVP, Finance and CFO CARYMPM ASSET MANAGEMENT II LLCBOSTONMPM ASSET MANAGEMENT II LLCBOSTONMPM ASSET MANAGEMENT II LPBOSTONMPM ASSET MANAGEMENT II LPBOSTONMPM ASSET MANAGEMENT INVESTORS 2001 LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2001 LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM BIOVENTURES II GMBH & CO PARALLEL BETEILIGUNGS KGBOSTONMPM BIOVENTURES II GMBH & CO PARALLEL BETEILIGUNGS KGBOSTONMPM BIOVENTURES II LPBOSTONMPM BIOVENTURES II LPBOSTONMPM BIOVENTURES II QP LP10% Owner BOSTONMPM BIOVENTURES II QP LP BOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONWalter  NewmanChief Scientific Officer/VP RD LEXINGTONWalter  NewmanCSO/SVP Research & Development LEXINGTONTrevor  PhillipsFormer President & CEO LEXINGTONAndrew Kenneth William  PowellEVP, General Counsel CARYDavid  PriceChief Financial Officer CARYDavid  PriceChief Financial Officer CARYSTEPHAN  ROBERTCARYAlan  RobertsVP, Scientific Affairs CARYAlan  RobertsVP, Scientific Affairs CARYPAUL D  RUBINPresident and CEO LEXINGTONLaura  ShawverDirector CARYLaura  ShawverDirector CARYMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZ BOSTONRobert  StephanPARMARobert  StephanDirector PARMAJAMES B  TANANBAUMPALO ALTOJAMES B  TANANBAUMDirector PALO ALTOFRANK E  THOMASLEXINGTONFRANK E  THOMASPresident & CEO LEXINGTONScott B  TownsendGENERAL COUNSEL and SVP LEGAL LEXINGTONScott B  TownsendGENERAL COUNSEL and EVP LEGAL CARYScott B  TownsendGENERAL COUNSEL and EVP LEGAL CARYMarco  VecchiaDirector PARMAMORGUS  VINCENTCARYCHRISTOPHER T PHD  WALSHDirector LEXINGTONHowland Shaw  WarrenDirector LEXINGTONHAROLD R  WERNERPRINCETONKURT  WHEELERBOSTONKURT  WHEELER BOSTONJeffrey E  YoungFORMER VP FINANCE & CAO LEXINGTONRobert H  ZeigerDirector LEXINGTONM Cory  ZwerlingDirector CARLISLEPersons related to MPM BIOVENTURES III QP LP - BARRIER THERAPEUTICS INCNamePositionCitySRINIVAS  AKKARAJUDirector MENLO PARKSRINIVAS  AKKARAJUDirector MENLO PARKSRINIVAS  AKKARAJUNEW YORKSRINIVAS  AKKARAJUDirector NEW YORKSRINIVAS  AKKARAJUNEW YORKALFRED  ALTOMARIChief Operating Officer PRINCETONALFRED  ALTOMARIChief Operating Officer PRINCETONALFRED  ALTOMARIChief Executive Officer PRINCETONBengal Acquisition Inc.10% Owner CORAL GABLESMARCEL  BORGERSChief Scientific Officer B-2440 GEELALBERT  BRISTOWGeneral Counsel and Secretary PRINCETONALBERT  BRISTOWGeneral Counsel and Secretary PRINCETONALBERT  BRISTOWGeneral Counsel & Corp Sec'y PRINCETONROBERT E  CAMPBELLDirector NORTH BRUNSWICKROBERT E  CAMPBELLDirector PRINCETONGEERT  CAUWENBERGHChief Executive Officer PRINCETONGEERT  CAUWENBERGHChief Executive Officer PRINCETONGEERT  CAUWENBERGHDirector PRINCETONANTHONY L  CRAIGWAYNECHRISTOPHER J  DAVISWAYNEMARK J  DENINOWAYNECarl  EhmannDirector CHARLESTONCarl  EhmannDirector PRINCETONEDWARD L  ERICKSONDirector PRINCETONEDWARD L  ERICKSONDirector PRINCETONPETER  ERNSTERDirector PRINCETONPETER  ERNSTERDirector PRINCETONLUKE  EVNIN10% Owner BOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONDENNIS  HENNERBOSTONJ P MORGAN CHASE & CONEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS A LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS A LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LPNEW YORKJ P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LPNEW YORKCharles F  Jacey JrDirector BELLE MEADCharles F  Jacey JrDirector PRINCETONJanssen Pharmaceutica Products, L.P.NEW BRUNSWICKJanssen Pharmaceutica Products, L.P.NEW BRUNSWICKJanssen Pharmaceutica Products, L.P.NEW BRUNSWICKJOHNSON & JOHNSON10% Owner NEW BRUNSWICKJohnson & Johnson Consumer Companies, Inc.NEW BRUNSWICKJohnson & Johnson Consumer Companies, Inc.NEW BRUNSWICKJohnson & Johnson Consumer Companies, Inc.NEW BRUNSWICKJOHNSON & JOHNSON DEVELOPMENT CORP ET ALNEW BRUNSWICKJOHNSON & JOHNSON DEVELOPMENT CORP ET ALNEW BRUNSWICKJP MORGAN PARTNERS BHCA LP10% Owner NEW YORKJP MORGAN PARTNERS BHCA LP10% Owner NEW YORKJP MORGAN PARTNERS BHCA LP10% Owner NEW YORKJP MORGAN PARTNERS BHCA LP10% Owner NEW YORKJP MORGAN PARTNERS BHCA LP10% Owner NEW YORKJP MORGAN PARTNERS GLOBAL INVESTORS LPNEW YORKJP MORGAN PARTNERS GLOBAL INVESTORS LPNEW YORKJP MORGAN PARTNERS GLOBAL INVESTORS LPNEW YORKJP MORGAN PARTNERS GLOBAL INVESTORS LPNEW YORKMORGAN PARTNERS GLOBAL INVESTORS SELLDOWN LLP  JPNEW YORKMORGAN PARTNERS GLOBAL INVESTORS SELLDOWN LLP  JPNEW YORKMORGAN PARTNERS GLOBAL INVESTORS SELLDOWN LLP  JPNEW YORKJPMP CAPITAL CORPNEW YORKJPMP CAPITAL CORPNEW YORKJPMP CAPITAL CORPNEW YORKJPMP GLOBAL INVESTORS L PNEW YORKJPMP GLOBAL INVESTORS L PNEW YORKJPMP GLOBAL INVESTORS L PNEW YORKJPMP GLOBAL INVESTORS L PNEW YORKJPMP MASTER FUND MANAGER L PNEW YORKJPMP MASTER FUND MANAGER L PNEW YORKJPMP MASTER FUND MANAGER L PNEW YORKROBERT E  KEITH JRWAYNECHRISTOPHER  MOLLERWAYNEMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONCHARLES  NOMIDESChief R&D Officer PRINCETONCHARLES  NOMIDESChief R&D Officer PRINCETONCHARLES  NOMIDESChief R&D Officer PRINCETONMARC J  OSTRODirector WAYNEFRANK H  PEARLWASHINGTONFRANK H  PEARLWASHINGTONFRANK H  PEARLWASHINGTONPERSEUS BIOTECH FUND PARTNERS LLCWASHINGTONPERSEUS BIOTECH FUND PARTNERS LLCWASHINGTONPERSEUS EC LLCWASHINGTONPERSEUS SOROS BIOPHARMACEUTICAL FUND LP10% Owner NEW YORKPERSEUS SOROS BIOPHARMACEUTICAL FUND LP NEW YORKPERSEUS SOROS BIOPHARMACEUTICAL FUND LPNEW YORKPERSEUS SOROS PARTNERS LLCWASHINGTONPERSEUS SOROS PARTNERS LLCNEW YORKPERSEUS SOROS PARTNERS LLCNEW YORKPERSEUSPUR LLCWASHINGTONPERSEUSPUR LLCWASHINGTONCarol  RaphaelDirector PRINCETONCarol  RaphaelDirector PRINCETONDennis  ReillyPRINCETONDennis  ReillyVP, Finance & PAO PRINCETONDennis  ReillyChief Financial Officer PRINCETONDR DREW  SCHIFFNEW YORKSFM AH LLCNEW YORKSFM AH LLCNEW YORKSFM AH LLCNEW YORKSFM PARTICIPATION LPNEW YORKSFM PARTICIPATION LPWASHINGTONSFM PARTICIPATION LPNEW YORKSFM PARTICIPATION LPNEW YORKBraham  ShrootChief Scientific Officer PRINCETONNICHOLAS J  SIMON IIIDirector BOSTONNICHOLAS J  SIMON IIIDirector BOSTONSOROS FUND MANAGEMENT LLCNEW YORKSOROS FUND MANAGEMENT LLCNEW YORKGEORGE  SOROSNEW YORKGEORGE  SOROSNEW YORKMICHAEL  STEINMETZBOSTONCharles W  StiefelCORAL GABLESCharles W  StiefelCORAL GABLESStiefel Laboratories, Inc.CORAL GABLESStiefel Laboratories, Inc.10% Owner CORAL GABLESTL VENTURES V INTERFUND LPWAYNETL VENTURES V LLCWAYNETL VENTURES V LP10% Owner WAYNETL VENTURES V MANAGEMENT LPWAYNEANNE  VANLENTExec. V.P., CFO and Treasurer PRINCETONANNE  VANLENTExec V.P., CFO and Treasurer PRINCETONANNE  VANLENTExec VP & CFO PRINCETONKURT  WHEELERBOSTONPersons related to MPM BIOVENTURES III QP LP - TERCICA INCNamePositionCityMICHAEL J  ASTRUEDirector BRISBANEAJAY  BANSALChief Financial Officer BRISBANEALEXANDER E  BARKASDirector PALO ALTOALEXANDER E  BARKASDirector PALO ALTOALEXANDER E  BARKASDirector PALO ALTOALEXANDER E  BARKASDirector PALO ALTOALEXANDER E  BARKASDirector PALO ALTOJEAN LUC  BELINGARDDirector PARISGEORGE M  BRIGHTSOUTH SAN FRANCISCOROSS G  CLARKSOUTH SAN FRANCISCOROSS G  CLARKCHIEF TECHNICAL OFFICER SOUTH SAN FRANCISCOROSS G  CLARKCHIEF TECHNICAL OFFICER BRISBANEASHLEY L  DOMBKOWSKISOUTH SAN FRANCISCODRAKENSBERG, L.P.NEW YORKKARIN  EASTHAMSAN DIEGOKARIN  EASTHAMDirector SOUTH SAN FRANCISCOKARIN  EASTHAMDirector BRISBANELUKE  EVNINSOUTH SAN FRANCISCOLUKE  EVNIN10% Owner BOSTONANSBERT  GADICKEBOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOSBOSTONNICHOLAS  GALAKATOSBOSTONANDREW J  GRETHLEINSOUTH SAN FRANCISCOANDREW J  GRETHLEINVICE PRESIDENT, MANUFACTURING SOUTH SAN FRANCISCOANDREW J  GRETHLEINSVP, Pharmacetical Operations BRISBANEFaheem  HasnainDirector BRISBANEDENNIS  HENNERSOUTH SAN FRANCISCODENNIS  HENNERDirector BOSTONDENNIS  HENNERDirector BOSTONDENNIS  HENNERDirector BOSTONDENNIS  HENNERDirector BOSTONRUSSELL C  HIRSCHPALO ALTORUSSELL C  HIRSCHPALO ALTOWAYNE T  HOCKMEYERGAITHERSBURGWAYNE T  HOCKMEYERSOUTH SAN FRANCISCOS.A.  Ipsen,PARISS.A.  Ipsen,10% Owner PARISOLLE  ISAKSSONGOTEBORG SWEDENOLLE  ISAKSSONDirector SOUTH SAN FRANCISCOCHRISTOPHE  JEANDirector PARISCHRISTOPHE  JEANDirector BOULOGNE BILLANCOURTHABIB  KAIROUZNEW YORKHABIB  KAIROUZNEW YORKKARIBA LLCNEW YORKRICHARD  KINGPresident and C.O.O. BRISBANEMARK  LESCHLYNEW YORKMARK  LESCHLYDirector NEW YORKMARK  LESCHLYDirector NEW YORKTIMOTHY P  LYNCHSOUTH SAN FRANCISCOTIMOTHY P  LYNCHCHIEF FINANCIAL OFFICER SOUTH SAN FRANCISCODAVID L  MAHONEYDirector SOUTH SAN FRANCISCODAVID L  MAHONEYDirector BRISBANEMPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLCBOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LLCBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONMICHAEL J  PARKERSOUTH SAN FRANCISCOMICHAEL J  PARKERVICE PRESIDENT, QUALITY SOUTH SAN FRANCISCO,PROSPECT ASSOCIATES II L PPALO ALTOPROSPECT ASSOCIATES II L PPALO ALTOPROSPECT ASSOCIATES II L PPALO ALTOPROSPECT MANAGEMENT CO II LLCPALO ALTOPROSPECT MANAGEMENT CO II LLCPALO ALTOPROSPECT VENTURE PARTNERS II LP10% Owner PALO ALTOPROSPECT VENTURE PARTNERS II LP10% Owner PALO ALTORHO CAPITAL PARTNERS INCNEW YORKRHO CAPITAL PARTNERS INCNEW YORKCAPITAL PARTNERS VERWALTUNGS GMBH  RHONEW YORKCAPITAL PARTNERS VERWALTUNGS GMBH  RHONEW YORKRHO MANAGEMENT TRUST INEW YORKRHO MANAGEMENT TRUST INEW YORKRHO MANAGEMENT VENTURES IV LLCNEW YORKRHO MANAGEMENT VENTURES IV LLCNEW YORKRHO VENTURES IV GMBH & CO BETEILIGUNGS KGNEW YORKRHO VENTURES IV GMBH & CO BETEILIGUNGS KGNEW YORKRHO VENTURES IV LPNEW YORKRHO VENTURES IV QP LPNEW YORKRHO VENTURES IV QP LP10% Owner NEW YORKCHRISTOPHER EUGENE  RIVERASnr VP, Commercial Operations SOUTH SAN FRANCISCOCHRISTOPHER EUGENE  RIVERASnr VP, Commercial Operations BRISBANESTEPHEN  ROSENFIELDSenior V.P. of Legal Affairs SOUTH SAN FRANCISCOSTEPHEN  ROSENFIELDExecutive VP of Legal Affairs BRISBANESTEPHEN  ROSENFIELDEVP- Legal Affairs; G.C. & Sec BRISBANEJOSHUA  RUCHNEW YORKJOSHUA  RUCHNEW YORKJOHN A  SCARLETTSOUTH SAN FRANCISCOJOHN A  SCARLETTCHIEF EXECUTIVE OFFICER SOUTH SAN FRANCISCOJOHN A  SCARLETTCHIEF EXECUTIVE OFFICER BRISBANEDAVID  SCHNELLPALO ALTODAVID  SCHNELLPALO ALTOTHOMAS H  SILBERGChief Operating Officer SOUTH SAN FRANCISCONICHOLAS J  SIMON IIISOUTH SAN FRANCISCONICHOLAS J  SIMON IIIBOSTONMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZBOSTONSAS  Suraypharm,PARISJAMES B  TANANBAUMPALO ALTOJAMES B  TANANBAUMPALO ALTOStein Thorsten  vonSVP and Chief Medical Officer SOUTH SAN FRANCISCOStein Thorsten  vonSVP and Chief Medical Officer BRISBANEIRA  WALLISSOUTH SAN FRANCISCOKURT  WHEELERSOUTH SAN FRANCISCOKURT  WHEELER10% Owner BOSTONTHOMAS G  WIGGANSDirector SOUTH SAN FRANCISCOTHOMAS G  WIGGANSDirector BRISBANESUSAN  WONGSOUTH SAN FRANCISCOSUSAN  WONGActing Chief Financial Officer SOUTH SAN FRANCISCOSUSAN  WONGVP Finance & Chief Acctg Offcr BRISBANECARL  WORRELLSOUTH SAN FRANCISCOPersons related to MPM BIOVENTURES III QP LP - Radius Health, Inc.NamePositionCityAuerbach  AlanCambridgeGadicke  AnsbertCambridgeALAN H  AUERBACHDirector LOS ANGELESALAN H  AUERBACHDirector CAMBRIDGEALAN H  AUERBACHDirector WALTHAMHarvey  B.CambridgeBIOTECH AG  BBSCHAFFHAUSENBIOTECH AG  BBSCHAFFHAUSEN, SWITZERLANDBIOTECH AG  BBSCHAFFHAUSENGROWTH N V  BIOTECH10% Owner CURACOGROWTH N V  BIOTECH10% Owner CURACAOLOUIS MD  BRENNERChief Medical Officer CAMBRIDGEBROOKSIDE CAPITAL INVESTORS L PBOSTONBROOKSIDE CAPITAL MANAGEMENT LLC10% Owner BOSTONBROOKSIDE CAPITAL PARTNERS FUND LPBOSTONBROOKSIDE CAPITAL PARTNERS FUND LPBOSTONLyttle  C.CambridgeJose  CarmonaChief Financial Officer NEWTOWN SQUAREJAMES H  CAVANAUGHPRINCETONJAMES H  CAVANAUGHCAMBRIDGEWillard H  DereDirector THOUSAND OAKSWillard H  DereWALTHAMWillard H  DereDirector WALTHAMASHLEY L  DOMBKOWSKISOUTH SAN FRANCISCOMark  DurandCAMBRIDGEStoner  ElizabethCambridgeLUKE  EVNIN BOSTONLUKE  EVNIN10% Owner BOSTONLUKE  EVNINBOSTONF2 Bio Ventures GP Ltd.ROAD TOWN, TORTOLAF2 Bio Ventures GP Ltd.TORTOLAF2 Bio Ventures GP Ltd.ROAD TOWN, TORTOLAF2 Bio Ventures V L.P.ROAD TOWN, TORTOLAF2 Bio Ventures V L.P.TORTOLAF2 Bio Ventures V L.P.ROAD TOWN, TORTOLAF2 Bioscience GP Ltd.GEORGE TOWNF2 Bioscience III, L.P.10% Owner GEORGE TOWNF2 Bioscience IV GP Ltd.GEORGE TOWNF2 Bioscience IV GP Ltd.GEORGE TOWNF2 Bioscience IV L.P.10% Owner GEORGE TOWNF2 Bioscience IV L.P.10% Owner GEORGE TOWNF2 Bioscience VI L.P.GEORGE TOWNF2 Capital LtdGEORGE TOWNF2 Capital Ltd10% Owner TORTOLAF2 Capital LtdTORTOLAF2 Capital LtdTORTOLALorraine A.  FitzpatrickChief Medical Officer WALTHAMJONATHAN  FLEMINGDirector CAMBRIDGEJONATHAN  FLEMINGCAMBRIDGETodd  FoleyCAMBRIDGETodd  FoleyBOSTONMichael  FrankenCAMBRIDGECATHY  FRIEDMANDirector SANTA CLARAAndrew J.  FromkinCAMBRIDGEANSBERT  GADICKEDirector BOSTONANSBERT  GADICKEDirector WALTHAMANSBERT  GADICKEDirector BOSTONANSBERT  GADICKEBOSTONNICHOLAS  GALAKATOS BOSTONNICHOLAS  GALAKATOS10% Owner BOSTONNICHOLAS  GALAKATOS10% Owner BOSTONJEAN PIERRE  GARNIERDirector HARTFORDHattersley  GaryCambridgeGlobeways Holdings LtdROAD TOWN, TORTOLAGlobeways Holdings LtdTORTOLAGlobeways Holdings LtdROAD TOWN, TORTOLAKurt  GravesDirector CAMBRIDGEKurt  GravesCAMBRIDGEKurt  GravesDirector CAMBRIDGEKurt  GravesDirector WALTHAMWilliam  GreeneSOUTH SAN FRANCISCOALAN G  HARRISChief Medical Officer CAMBRIDGEALAN G  HARRISChief Medical Officer WALTHAMBrian Nicholas  HarveySr. VP and CFO CAMBRIDGEBrian Nicholas  HarveySr VP & CFO, Sec. & Treasurer CAMBRIDGEBrian Nicholas  HarveySr. Vice President & CFO WALTHAMGary  HattersleyChief Scientific Officer CAMBRIDGEGary  HattersleySr. VP & Chief Scientific Off. CAMBRIDGEGary  HattersleyChief Scientific Officer WALTHAMBrent  Hatzis-SchochSr. VP, General Counsel WALTHAMHealthCare Partners VII, L.P.PRINCETONHealthCare Partners VII, L.P.CAMBRIDGEPrivate Equity Limited Partnership  HealthcareEDINBURGHHEALTHCARE VENTURES VII LPPRINCETONHEALTHCARE VENTURES VII LP10% Owner CAMBRIDGEDENNIS  HENNERSOUTH SAN FRANCISCODENNIS  HENNERBOSTONDENNIS  HENNERBOSTONJesper  HoilandPresident and CEO WALTHAMOwen  HughesDirector CAMBRIDGEOwen  HughesDirector WALTHAMPharma SAS  IpsenBOULOGNE BILLANCOURTS.A.  Ipsen,BOULOGNE BILLANCOURTFleming  JonathanCambridgeMorana  Jovan-EmbiricosDirector CAMBRIDGEMorana  Jovan-EmbiricosDirector CAMBRIDGEMorana  Jovan-EmbiricosDirector WALTHAMVAUGHN M  KAILIANVAUGHN M  KAILIANBOSTONVAUGHN M  KAILIANBOSTONGraves  KurtCambridgeAUGUSTINE  LAWLORCAMBRIDGEJOHN W  LITTLECHILDCAMBRIDGEO'Dea  LouisCambridgeCecil Richard  LyttlePresident and C.E.O. CAMBRIDGECecil Richard  LyttlePresident and CEO CAMBRIDGECecil Richard  LyttleCAMBRIDGEMuenchbach  MartinCambridgeChristopher  MirabelliCAMBRIDGEMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLCBOSTONMPM Bio IV NVS Strategic Fund LPBOSTONMPM Bio IV NVS Strategic Fund LPBOSTONMPM BIOVENTURES III GMBH & COBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GMBH & CO. Beteiligungs KGBOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP L.P.BOSTONMPM BIOVENTURES III GP LPBOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III L.P.BOSTONMPM BIOVENTURES III LLC BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LLC10% Owner BOSTONMPM BIOVENTURES III LPBOSTONMPM BIOVENTURES III PARALLEL FUNDBOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III PARALLEL FUND, L.P.BOSTONMPM BIOVENTURES III-QP L.P.BOSTONMPM BIOVENTURES III-QP L.P.BOSTONMPM BioVentures IV GP LLCBOSTONMPM BioVentures IV GP LLCBOSTONMPM BioVentures IV LLC10% Owner BOSTONMPM BioVentures IV LLC10% Owner BOSTONMartin  MuenchbachDirector SAN DIEGOMartin  MuenchbachDirector CAMBRIDGEMartin  MuenchbachDirector CAMBRIDGEMartin  MuenchbachDirector CAMBRIDGEMartin  MuenchbachDirector WALTHAMBioscience Clinical Development VII A/S  NordicHERLEVBioscience Clinical Development VII A/S  Nordic10% Owner HERLEVLouis  O'DeaCAMBRIDGEKatherine  PriestleyGEORGE TOWNKatherine  PriestleyLONDONKatherine  PriestleyLONDONKatherine  PriestleyLONDONDinesh  PurandareSVP, Head of Global Oncology WALTHAMAnthony  RosenbergDirector CAMBRIDGEDebasish  RoychowdhuryDirector WALTHAMJames Paul  ScopaS. SAN FRANCISCOJames Paul  ScopaSOUTH SAN FRANCISCONICHOLAS J  SIMON IIISOUTH SAN FRANCISCONICHOLAS J  SIMON IIIBOSTONNICHOLAS J  SIMON IIIBOSTONDavid P.  SnowChief Commercial Officer WALTHAMPeter Steven  StBOSTONPeter Steven  StBOSTONMICHAEL  STEINMETZSAN DIEGOMICHAEL  STEINMETZBOSTONMICHAEL  STEINMETZBOSTONElizabeth  StonerDirector BOSTONElizabeth  StonerBOSTONElizabeth  StonerDirector WALTHAMVort John  VanderBOSTONVort John  VanderBOSTONVort John  VanderBOSTONRob  WardPresident & CEO PALO ALTORobert  WardPresident & CEO CAMBRIDGERobert  WardPresident & CEO CAMBRIDGERobert  WardPresident & Chief Exec Officer WALTHAMWELLCOME TRUST LTDLONDON NW1 2BEWELLCOME TRUST LTD10% Owner LONDONWELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST10% Owner LONDONHAROLD R  WERNERPRINCETONHAROLD R  WERNERCAMBRIDGEKURT  WHEELERBOSTONKURT  WHEELERBOSTONKURT  WHEELERBOSTONGregory C.  WilliamsChief Development Officer CAMBRIDGEGregory C.  WilliamsChief Development Officer CAMBRIDGEGregory C.  WilliamsChief Development Officer WALTHAMMICHAEL S  WYZGAChief Executive Officer CAMBRIDGEJohn  YatesCAMBRIDGEJohn  YatesChief Medical Officer CAMBRIDGE
Potentially same personNameCityCountryMPM BIOVENTURES III QP LPBOSTONMAMPM BIOVENTURES III QP LPBOSTONMAMPM BIOVENTURES III QP LPBOSTONMA












 









MPM BIOVENTURES II QP LP Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      MPM BIOVENTURES II QP LP
                    

•   BOSTON, MA
                      
How do I update this listing?




                                             MPM Bioventures II QP is based out of Boston.    WhaleWisdom has at least 19 13D/G filings in our database for MPM Bioventures II QP.
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from MPM BIOVENTURES II QP LP, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




mpm bioventures ii qp lp


THE JOHN HANCOCK TOWER

BOSTON
MA
                                                        
                                                    02116


              Business Phone:
              6174259200







Recent SEC Filings




SC 13G/A filed on 02/05/2015
SC 13G filed on 02/12/2014
SC 13G/A filed on 02/12/2014
SC 13G filed on 02/13/2006
SC 13G filed on 02/13/2006
SC 13D filed on 02/13/2006
SC 13D filed on 02/13/2006











Current 13D/G Holdings


Stock
Sector
Shares Held
Market Value
Rank
Source
Source Date





HemoSense Inc. (HEM)


      HEALTH CARE
    

      4,345,944
    

      25,467,231.84
    

      1
    

      13G
    

      2005-12-31
    



Restore Medical Inc (REST)


      HEALTH CARE
    

      4,435,084
    

      18,671,703.64
    

      2
    

      13G
    

      2006-12-31
    



Unknown (unknown)




      2,672,568
    



      3
    

      13D
    

      2007-06-21
    











Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free




















Insider Trading - Mpm Bioventures Iii-qp L.P. - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Mpm Bioventures Iii-qp L.P.





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-09-27Other
2016-09-296:04 pm
N/AN/A
Radius Health Inc.
RDUS
Mpm Bioventures III LLCHenner DennisMpm Asset Management Investors 2003 Bviii LLCMpm Bioventures III Gmbh & CO. Beteiligungs KgMpm Bioventures III Parallel Fund L.P.Mpm Bioventures III Gp L.P.Mpm Bioventures III L.P.Mpm Bioventures Iii-qp L.P.Steinmetz MichaelOther
1,229,902
$0
2,459,804(Indirect)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Sat, 22 Jul 2017 19:57:11 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  













SEC Info - MPM Bioventures III-QP L.P., et al. - �3� for 12/14/05 re: Pernix Sleep, Inc. - Filing Submission










SEC Info uses JavaScript!� To view pages properly, enable JavaScript in your browser.


����SEC Info������Home������Search������My Interests������Help������Sign In������Please Sign In



��Installed latest Microsoft security patches.� Rebooting now.� Up as soon as possible...�

MPM Bioventures III-QP L.P., et al. � �3��for�12/14/05 re:�Pernix Sleep, Inc.On:� Wednesday, 12/14/05, at 8:43pm ET � � � For:� 12/14/05 � � � As:� 10% Owner � � � Accession #:� 1209191-5-63379 � � � File #:� 0-51665
Previous ‘3’:� ‘3’ on / for 10/15/04 � � � Next:� ‘3’ on 4/27/06 for 4/26/06 � � � Latest:� ‘3’ on 8/10/12 for 8/11/12



��in�
this entire Filing.
an "Entity" Search.
��Show�
Docs searched
�and�
every "hit".
the 1st "hit".

Help...�Wildcards:� ? (any letter),� * (many).� Logic:� for Docs:� &�(and),� |�(or);� for Text:� |�(anywhere),� "(&)"�(near).� � ↓Bottom
�
T-->  As Of                Filer                Filing    For�On�As Docs:Size              Issuer               Agent

12/14/05  MPM Bioventures III-QP L.P.       3          10% Owner   1:14K  Pernix Sleep, Inc.                RR Donnelley File16/FA
          MPM Bioventures III LP
          MPM Bioventures III Parallel Fund, LP
          MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
          MPM Bioventures III GP LP
          MPM Bioventures III LLCF-->Initial Statement of Beneficial Ownership of Securities � � � Form 3Filing Table of Contents
Document/Exhibit                   Description                      Pages   Size 

 1: 3           Initial Statement of Beneficial Ownership of        HTML     11K 
                          Securities -- bsf15471_bsf1mpm.xml/2.2                 

_-->Filing Submission 0001209191-05-063379 – SGML TextRaw SGML-Tagged Text that was Submitted by:� DONNELLEY FINANCIAL SOLUTIONS File16/FA �(as�Filing�Agent)Show all <DOCUMENT> <TEXT> elements below� � � � � � � � � ↑Top ↓Bottom�
<SUBMISSION>                                                                    
<ACCEPTANCE-DATETIME>		20051214204332
<ACCESSION-NUMBER>		0001209191-05-063379
<TYPE>				3
<PUBLIC-DOCUMENT-COUNT>		1
<PERIOD>			20051214
<FILING-DATE>			20051214
<DATE-OF-FILING-DATE-CHANGE>	20051214
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>		MPM BIOVENTURES III QP LP
<CIK>				0001173409
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>			3
<ACT>				34
<FILE-NUMBER>			000-51665
<FILM-NUMBER>			051265113
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			111 HUNTINGTON AVENUE
<STREET2>			31ST FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02199
<PHONE>				617 425 9200
</BUSINESS-ADDRESS>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIO VENTURES III QP LP
<DATE-CHANGED>			20020514
</FORMER-NAME>
</REPORTING-OWNER>
<ISSUER>
<COMPANY-DATA>
<CONFORMED-NAME>		Somaxon Pharmaceuticals, Inc.
<CIK>				0001339455
<ASSIGNED-SIC>			2834
<IRS-NUMBER>			200161599
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</COMPANY-DATA>
<BUSINESS-ADDRESS>
<STREET1>			12750 HIGH BLUFF DRIVE, SUITE 310
<CITY>				SAN DIEGO
<STATE>				CA
<ZIP>				92130
<PHONE>				(858) 509-3670
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			12750 HIGH BLUFF DRIVE, SUITE 310
<CITY>				SAN DIEGO
<STATE>				CA
<ZIP>				92130
</MAIL-ADDRESS>
</ISSUER>
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>		MPM BIOVENTURES III LP
<CIK>				0001173408
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>			3
<ACT>				34
<FILE-NUMBER>			000-51665
<FILM-NUMBER>			051265115
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 5TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
<PHONE>				617 425 9200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 5TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
</MAIL-ADDRESS>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIO VENTURES III LP
<DATE-CHANGED>			20020514
</FORMER-NAME>
</REPORTING-OWNER>
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>		MPM BIOVENTURES III PARALLEL FUND, LP
<CIK>				0001249063
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>			3
<ACT>				34
<FILE-NUMBER>			000-51665
<FILM-NUMBER>			051265117
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
<PHONE>				6174259200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
</MAIL-ADDRESS>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIOVENTURES III PARALLEL FUND
<DATE-CHANGED>			20031124
</FORMER-NAME>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIO VENTURES III PARALLEL FUND
<DATE-CHANGED>			20030627
</FORMER-NAME>
</REPORTING-OWNER>
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>		MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
<CIK>				0001249133
<STATE-OF-INCORPORATION>	2M:  This is an SEC-specific code that maps to 
				Germany {DE}
<FISCAL-YEAR-END>		1231
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>			3
<ACT>				34
<FILE-NUMBER>			000-51665
<FILM-NUMBER>			051265116
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
<PHONE>				6174259200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
</MAIL-ADDRESS>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIOVENTURES III GMBH & CO
<DATE-CHANGED>			20031124
</FORMER-NAME>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIO VENTURES III GMBH & CO
<DATE-CHANGED>			20030627
</FORMER-NAME>
</REPORTING-OWNER>
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>		MPM BIOVENTURES III GP LP
<CIK>				0001249143
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>			3
<ACT>				34
<FILE-NUMBER>			000-51665
<FILM-NUMBER>			051265114
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
<PHONE>				6174259200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
</MAIL-ADDRESS>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIO VENTURES III GP LP
<DATE-CHANGED>			20030627
</FORMER-NAME>
</REPORTING-OWNER>
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>		MPM BIOVENTURES III LLC
<CIK>				0001249147
<FISCAL-YEAR-END>		1231
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>			3
<ACT>				34
<FILE-NUMBER>			000-51665
<FILM-NUMBER>			051265118
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
<PHONE>				6174259200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			THE JOHN HANCOCK TOWER
<STREET2>			200 CLARENDON STREET, 54TH FLOOR
<CITY>				BOSTON
<STATE>				MA
<ZIP>				02116
</MAIL-ADDRESS>
<FORMER-NAME>
<FORMER-CONFORMED-NAME>		MPM BIO VENTURES III LLC
<DATE-CHANGED>			20030627
</FORMER-NAME>
</REPORTING-OWNER>
</SUBMISSION>↑Top
Filing Submission 0001209191-05-063379 � – � Alternative Formats (Word / Rich Text, HTML, Plain Text, et�al.)
Copyright � 2017 Fran Finnegan & Company.� All Rights Reserved.About – Privacy – Redactions – Help —
Sun, 23 Jul 00:57:12.1 GMT�
 










MPM Capital - Powering Breakthroughs in Life Sciences





























































MPM Focus Area
Personalized therapeutics forgenetically defined cancerWatch Now Chris Bardon, MD Oncology Impact FundDiscusses Advances in Cancer Therapies Bloomberg Capital Markets, June 2016
Related Investment: Epizyme





Companies









MPM Investment Strategy 
				MPM Capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas. MPM is currently investing out of BV2014, its most recent venture fund. In 2015 MPM partnered with UBS to create the UBS Oncology Impact Fund (OIF), an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities. OIF will support both basic cancer research as well as access to cancer care in developing countries. 			




Fund

All
BV2014
Oncology Impact Fund



Investments

Current
Exited



Exit Type

All
IPO
M&A



Focus Area

All
Oncology
Other










23andMe
Genetic reports for consumers to better appreciate their ancestry

Other
Current









28-7
Small-molecule therapeutics that modulate miRNAs for treatment

Oncology
Current









Affymax, Inc.
Previously committed to developing novel drugs

Other
Exited









Aires
Clinical stage pharmaceutical company for pulmonary disorders

Other
Exited









Alinea Pharmaceuticals, Inc.
Previously developed new treatments for metabolic conditions

Other
Exited









Allozyne, Inc.
Cancer and inflammatory disease therapeutic company

Oncology
Exited









Alnara
Orally-delivered protein therapeutics to treat metabolic diseases

Other
Exited









Amphivena
Developing bispecific TandAbs as a novel immunotherapy for hematological disorders

Oncology
Current









Anthera
Developing drugs for autoimmune diseases

Other
Exited









Aratana
Provides innovative therapies for companion animals

Other
Current









Archus Orthopedics, Inc.
Previously developed implants to treat spine disorders 

Other
Exited









ARYx Therapeutics, Inc.
Previously focused on molecular design

Other
Exited









Astute Medical
Improving the diagnosis of high-risk medical conditions

Other
Current









Atopix Therapeutics, Inc.
Developing novel treatments for asthma

Other
Exited









Barrier Therapeutics, Inc.
Specialized in dermatological creams and gels

Other
Exited









BioMarin
Innovative therapeutics to patients with serious unmet medical needs

Other
Exited









Blade Therapeutics
A discovery stage company focused on developing fibrosis treatments

Other
Current









Celladon
Developing a transformative therapy for heart failure

Other
Exited









Cellerant Therapeutics, Inc.
novel immunotherapies for oncology and blood-related disorders

Oncology
Exited









Cerecor Inc.
Developing innovative treatments for patients with CNS disorders

Other
Exited









Ceregene, Inc.
Development and manufacturing of gene therapies 

Other
Exited









Cerimon Pharmaceuticals, Inc.
Developed and commercialized therapeutics for autoimmune diseases

Other
Exited









CHF Solutions, Inc.
Manufactures medical devices for cardiac care. 

Other
Exited









Chiasma
Developing oral drugs that were previously only available by injection

Other
Current









Clinical ink
Modernize clinical trials with eSource & patient engagement tools

Other
Current









Conatus
Developing novel therapeutics for liver diseases

Other
Exited









CoStim
Developing novel antibodies for cancer immunotherapy

Oncology
Exited









CoTherix, Inc.
Licensing of therapeutic products for cardiopulmonary diseases

Other
Exited









DigiTx Partners
Digital health investment partnership with Astellas Pharma

Other
Current









Dragonfly Sciences, Inc.
developing a new class of biosimilar products

Other
Exited









EKR Therapeutics
Provides acute-care specialty products

Other
Exited









Elixir Pharmaceuticals, Inc.
Develops novel pharmaceuticals for the treatment of metabolic diseases

Other
Exited









EndoGastric Solutions, Inc.
Endoluminal treatment of gastroesophageal reflux disease

Other
Exited









Endologix
Provides optimal solutions for endovascular aortic repair

Other
Current









EnteroMedics, Inc.
developer of vBloc® neurometabolic therapy

Other
Current









Epizyme
Personalized therapeutics for patients with genetically defined cancer

Oncology
Current









ForteBio
Develops analytical systems that enable real-time analysis of biomolecular interactions 

Other
Exited









Harpoon Therapeutics
T cell redirection to deliver deep remissions

Oncology
Current









Helicos Biosciences Corporation
Genetic analysis for the research, drug discovery and diagnostics 

Other
Exited









Hypnion, Inc.
development of novel therapeutics for (CNS) disorders

Other
Exited









Iconic
Developing therapeutics for serious eye disorders

Other
Current









Idenix
Discovers and develops drugs for human viral diseases

Other
Exited









IDUN Pharmaceuticals, Inc.


Other
Exited









Innovative Spinal Technologies, Inc.
Developed treatments for spinal disorders 

Other
Exited









Intercell AG
Modern prophylactic and therapeutic vaccines 

Other
Exited









Intracel Holdings Corporation
Development and commercialization of cancer vaccines

Other
Exited









IOmx Therapeutics AG
Targeting T cell evasion to treat cancer

Oncology
Current









iPierian
Developing anti-Tau protein antibodies for neurodegenerative disease

Other
Exited









KaloBios Pharmaceuticals, Inc.
developing monoclonal antibodies for cancer care

Oncology
Exited









MacroGenics, Inc.


Oncology
Exited









Maverick Therapeutics, Inc.
Inducible T cell-redirecting antibodies

Oncology
Current









Memory Pharmaceuticals Corp.
Developed drug candidates for the treatment of CNS disorders

Other
Exited









Meritage Pharma
Treatment for eosinophilic esophagitis (EoE)

Other
Exited









Mitobridge
Discovers and develops novel drugs that enhance mitochondrial function

Other
Current









Motus Therapeutics, Inc.
Developing therapies for severe gastric mobility disorders

Other
Exited









Neosil
Manufactures dermatology-focused specialty pharmaceutical products

Other
Exited









NeoVista, Inc.
Technologies for age related mucular degeneration

Other
Exited









NeuroMed Pharmaceuticals, Inc.
Produces pain therapies in the US

Other
Exited









Nevro
Developing a high-frequency stimulation technology for chronic pain

Other
Exited









Oncorus
Developing a next-generation immunotherapy platform to treat cancer

Oncology
Current









Oxagen Limited
A privately-held biopharmaceutical company

Other
Current









Pacira
Acute care products including EXPAREL for post-surgical analgesia

Other
Exited









Peptimmune, Inc.
Designs peptides for therapeutics, diagnostic kits & antibodies

Other
Exited









Pernix Therapeutics, Inc.
Specialty, primary care and generic medicines

Other
Exited









Pharmasset
Discovering and developing novel drugs to treat viral infections

Other
Exited









PharmAthene, Inc.
Acquire and develop products identified as urgent priorities

Other
Exited









Poniard Pharmaceuticals, Inc.
Discovery, development and commercialization of oncology products

Other
Exited









Portola Pharmaceuticals, Inc.
A biopharmaceutical company in the hematologic diseases fields 

Other
Exited









Potenza Therapeutics
Developing novel immunotherapies for the treatment of cancer

Oncology
Current









Proteon Therapeutics
Developing a therapy to improve dialysis vascular access

Other
Current









QuatRx Pharmaceuticals Company
Treatment of moderate to severe dyspareunia FDA approved in Feb 2013

Other
Exited









Radius Health
Novel, differentiated therapeutics for patients with osteoporosis

Other
Current









Raze Therapeutics
Developing novel anti-tumor agents through mitochondrial one-carbon me

Oncology
Current









Repare Therapeutics
Targeting genetically-defined cancer weaknesses

Oncology
Current









Rhythm
Developing peptide therapeutics for metabolic diseases

Other
Current









Rigel Pharmaceuticals, Inc.
Small-molecule development for inflammatory and autoimmune diseases

Oncology
Exited









Rinat Neuroscience Corp.
Develops treatment of diseases and disorders of the nervous system

Other
Exited









SAI
Drug discovery, development, and manufacturing services

Other
Exited









Selexys
Developing novel products to treat inflammatory diseases

Other
Exited









Semma Therapeutics
Developing cell-based transformative therapies for diabetes patients

Other
Current









Sideris Pharmaceuticals, Inc.
Development of new treatments for transfusion related iron overload

Other
Exited









Solasia
Developing, commercializing oncology & oncology supportive care drugs

Oncology
Exited









Somaxon Pharmaceuticals, Inc.
Developed Silenor for treatment of insomnia 

Other
Exited









Surface Logix, Inc.
Enhancing molecular functionality of pharmaceuticals

Other
Exited









Syndax
Developing and commercializing epigenetic therapies for cancer

Oncology
Current









TCR2, Inc.
Focused on engineering T cells for cancer therapy

Oncology
Current









Tercica, Inc.
Developed Increlex for treatment of primary IGF-1 deficiency

Other
Exited









Tetherex Pharmaceuticals Corporation
Operates in the healthcare industry focusing on biotechnology business

Other
Current









Theraclone Sciences, Inc.
Screening technology for antibodies that ward off disease 

Other
Exited









Tizona Therapeutics, Inc.
Regulatory T cell suppression as a novel approach to fighting cancer

Oncology
Current









Trieza Therapeutics
Immunomodulatory oncolytic virus therapeutics

Oncology
Current









TriNetX
Platform to improve clinical research, study design & recruitment

Other
Current









True North Therapeutics
Developing drugs which selectively inhibit the complement system

Other
Exited









Vaccinogen, Inc.
Personalized vaccines to fight disease 

Oncology
Other
Current









Valeritas
Marketing a disposable insulin delivery device

Other
Current









Vascular
Developing a novel antibody for diabetic nephropathy

Other
Current









Verastem, Inc.
Treating cancer by the targeted killing of cancer stem cells

Oncology
Exited









Verus Pharmaceuticals, Inc.
 Pediatric-oriented specialty pharmaceutical company

Other
Exited









Xanodyne Pharmaceuticals, Inc.
Integrated specialty pharmaceutical company 

Other
Exited
















MPM Team
				MPM's Team is comprised of innovators, entrepreneurs, executives & investors			



Role

Investment Team
Medical & Scientific Advisors
Operations Team



Location

All
Cambridge
San Francisco










									Patrick Baeuerle								


Patrick Baeuerle, Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Chris  Bardon								


Christiana Bardon, M.D.
Managing Director

																					Cambridge																			
Read Bio







									Vinay Bhaskar								


Vinay Bhaskar, Ph.D.
Principal

																					San Francisco 																			
Read Bio







									Laura Brass 								


Laura Brass, Ph.D., M.B.A.
Managing Director

																					Cambridge 																			
Read Bio







									Lauren Cauley								


Lauren Cauley
Chief Financial Officer

																					Cambridge 																			
Read Bio







									Thomas Ebeling								


Thomas Ebeling
Medical and Scientific Advisor (OIF)


Read Bio







									Stephen Elledge								


Stephen J. Elledge,  Ph.D.
MEDICAL AND SCIENTIFIC  ADVISORY BOARD (MPM & OIF)


Read Bio







									Luke Evnin								


Luke Evnin, Ph.D.
Managing Director

																					San Francisco 																			
Read Bio







									Mitchell  Finer Ph.D.								


Mitchell Finer Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Todd Foley								


Todd Foley, M.B.A.
Managing Director

																					Cambridge 																			
Read Bio







									Shinichiro Fuse								


Shinichiro Fuse, Ph.D.
Principal

																					Cambridge 																			
Read Bio







									Ansbert Gadicke								


Ansbert Gadicke, M.D.
Managing Director

																					Cambridge 																			
Read Bio







									Bard Geesaman								


Bard Geesaman, M.D., Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									William Greene								


William Greene, M.D.
Venture Partner

																					San Francisco 																			
Read Bio







									William Hahn								


William C. Hahn, M.D., Ph.D.
Medical and Scientific Advisor (OIF)


Read Bio







									Dan Hicklin								


Dan Hicklin, Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Robert Horvitz								


H. Robert Horvitz, Ph.D.
Medical and Scientific Advisory Board (MPM & OIF)


Read Bio







									Ed Hurwitz								


Ed Hurwitz, J.D., M.B.A.
Managing Director

																					San Francisco 																			
Read Bio







									Briggs Morrison								


Briggs Morrison, M.D.
Managing Director

																					Cambridge 																			
Read Bio







									Vas Narasimhan								


Vas Narasimhan, M.D.
Medical and Scientific Advisory Board (MPM)


Read Bio







									Gary Patou								


Gary Patou, M.D.
Managing Director

																					San Francisco 																			
Read Bio







									Sarah Reed								


Sarah Reed
Chief Operating Officer and General Counsel

																					Cambridge 																			
Read Bio







									Tony Rosenberg								


Tony Rosenberg
Managing Director

																					Cambridge 																			
Read Bio







									David Ryan								


David P. Ryan, M.D.
Medical & Scientific Advisor (OIF)


Read Bio







									Kazumi Shiosaki								


Kazumi Shiosaki, Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Greg Sieczkiewicz								


Greg Sieczkiewicz, J.D., Ph.D.
Managing Director & Chief IP Counsel

																					Cambridge 																			
Read Bio







									Elizabeth Stoner								


Elizabeth Stoner, M.D.
Managing Director

																					Cambridge 																			
Read Bio







									Chris Varma								


Chris Varma, Ph.D.
Entrepreneur-in-Residence

																					Cambridge 																			
Read Bio














Contact Us

info@mpmcapital.com



Cambridge, MA


								450 Kendall Street								
								Cambridge, MA  02142								


Phone | 617-425-9200

 


see full map / get directions

 

San Francisco, CA


								601 Gateway Boulevard								
								Suite 350								
																    South San Francisco, 
																CA 
								94080								

Phone | 650-553-3300

 


see full map / get directions

 
 



 

Print

Terms Of Use & Disclosures














2017

June 28, 2017
Semma Therapeutics Mentioned in WSJ article “Biotech Startups’ Cell-Based Diabetes Attack”



June 22, 2017
MPM and Versant Venture Co-Lead Series A Financing of Repare Therapeutics



June 21, 2017
Proteon Therapeutics Announces $22.0 Million Private Placement



June 20, 2017
Visionary Scientist Stephen J. Elledge Joins MPM Capital’s Medical and Scientific Advisory Board



June 13, 2017
Accomplished Oncologist and Scientist William C. Hahn Joins MPM Capital’s Oncology Impact Fund Advisory Board



June 8, 2017
TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress



June 6, 2017
Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)



May 25, 2017
Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform



May 25, 2017
Harpoon Therapeutics Announces Completion of $45M Series B Financing



May 23, 2017
MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc
Upfront payment of $400M plus assumed cash, with additional payments of up to $425M contingent on the achievement of future milestones


May 18, 2017
Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle



May 4, 2017
Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis



May 3, 2017
Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon



April 28, 2017
FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)
Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture


April 17, 2017
Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle



April 5, 2017
MPM Managing Director Chris Bardon Named a Top-40 Transformer
Top innovation gurus leading the biopharma industry's transformation are recognized by MM&M  


April 4, 2017
MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics



April 4, 2017
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors



February 16, 2017
Rhythm Announces Completion of $41 Million Mezzanine Financing
— Proceeds to finance significant expansion of genetic obesity clinical trials —


February 7, 2017
Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence



January 11, 2017
MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies



January 5, 2017
Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director


2016 
December 19, 2016
MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne



December 19, 2016
Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.



December 15, 2016
Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC



December 13, 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO



December 8, 2016
TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies
- $44.5M Series A Financing Led by MPM Capital and F2 Ventures -


December 2, 2016
Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy
Read full article – “A Few Billionaires Are Turning Medical Philanthropy on Its Head” 


November 28, 2016
Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update



November 21, 2016
Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease



November 8, 2016
Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer



November 7, 2016
Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman



October 31, 2016
MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute



October 27, 2016
Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan
Acquisition Announced Following Positive Results for Phase 2b Clinical Trial of Treatment for GI Disorders


October 18, 2016
True North Therapeutics Announces $45 Million Series D Financing
Financing Follows Encouraging Interim Clinical Data Announced for Lead Product Candidate, TNT009, in Cold Agglutinin Disease


October 13, 2016
True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)



October 11, 2016
Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”
Learn why Kristen stands out among women in the industry


September 22, 2016
iOmx Therapeutics Raises EUR 40 Million in Series A round
Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures


September 19, 2016
Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List



September 19, 2016
Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment



September 14, 2016
Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors



August 16, 2016
Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More
 Read coverage in NY Times and in Press Release


August 15, 2016
Aratana Secures Third FDA Approval
Animal pain drug expected to be available to veterinarians in the fall of 2016


August 11, 2016
Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean
Read more in The Boston Globe


August 10, 2016
Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment



August 1, 2016
Astellas and MPM Capital Launch DigiTx Partners



July 26, 2016
MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times
The July 19 article, “Taking it personally, cutting–edge biotech snags $45 million,” discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnin’s personal commitment to the cause.


July 21, 2016
Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
Significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway


July 20, 2016
Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A



June 16, 2016
MPM Portfolio Company Semma Therapeutics Featured in Boston Globe
Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.


June 2, 2016
Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets
Discussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets Underway


May 27, 2016
TriNetX Enters into Collaboration with Celgene
Advance Clinical Trial Design and Research for Next-Generation Medicines Planned


May 18, 2016
Aratana Therapeutics Granted FDA Approval of ENTYCE®
First-of-its-Kind Ghrelin Mimetic


May 3, 2016
MPM Launches $471 Million Social Impact Oncology Fund



April 29, 2016
UBS Cancer Fund Shows Power of Impact Investing
A new oncology fund will finance academic research and access to cancer care in developing countries


April 28, 2016
UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund
By Marie Powers, BioWorld Today, April 28, 2016


April 27, 2016
UBS Raises Record $471 Million for Oncology Impact Fund
BioSpace.com 4/27/2016


March 21, 2016
Aratana Therapeutics Granted First FDA Approval
Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs


March 14, 2016
Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly



March 8, 2016
Tizona Therapeutics, Inc., Completes $43 Million Series B Financing



March 6, 2016
Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis



March 3, 2016
Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market



January 9, 2016
Iconic Therapeutics Closes Series C Financing


2015 
October 15, 2015
Cerecor Announces Pricing of Initial Public Offering



October 15, 2015
Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15



August 27, 2015
Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab



August 24, 2015
Syndax Raises $80 Million in Series C Financing



August 17, 2015
Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing
Financing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesity


August 15, 2015
Epizyme Appoints Robert Bazemore President and Chief Executive Officer



July 16, 2015
Chiasma, Inc. Prices Initial Public Offering of Common Stock



July 10, 2015
Taking Clinical Trials Out of the Dark Ages (Clinical Ink)



June 23, 2015
Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor  to MPM Capital



June 15, 2015
Chiasma Submits New Drug Application to U.S. FDA  for Octreotide Capsules in Acromegaly
Submission based on positive results from Phase 3 clinical trial


June 1, 2015
K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor



May 21, 2015
MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius



May 14, 2015
MPM closes $400 million fund



May 5, 2015
23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.
With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the Disease


April 22, 2015
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
Exclusive Collaboration Includes Option for Astellas to Acquire Potenza


April 15, 2015
Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015
- To serve as strategic advisor and on MPM portfolio boards to build leading companies -


March 24, 2015
Biotech Startup to Fight Diabetes on the Cellular Front
Semma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin production


March 24, 2015
Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company



March 16, 2015
Ebb & Flow: Chiasma’s Private Decision



March 16, 2015
Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Proven Business Leader to Oversee Commercialization of Octreotide Capsules


March 12, 2015
23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
Dr. Scheller Joins 23andMe’s Executive Leadership Team as Chief Science Officer and Head of Therapeutics


March 11, 2015
MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director
-Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries 


March 10, 2015
Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan
Dinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius )


February 27, 2015
Chiasma Announces Completion of $70 Million Series E Financing



February 27, 2015
Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma



February 24, 2015
Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors



February 20, 2015
Syndax Says Immuno-oncology Discovery Happened Instead of an IPO



February 10, 2015
Chiasma Inc. Releases Newly Published Phase 3 Study Results
Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder


February 9, 2015
Radius, Celladon and Nevro Among Top IPOs in 2014
MPM has #1, 8 and 10 out of the top 14


January 1, 2015
Radius:  The Top Performing IPO of 2014
Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 8

2014 
December 22, 2014
Radius Announces Positive Phase 3 Top-Line Results



December 15, 2014
For Venture Capital, Biotech is Where It’s Really At



August 4, 2014
Aratana Featured:  Start-Ups Work on Biotech Drugs for Pets



July 22, 2014
Cerecor Inc. Closes on Initial Tranche of US$32M Series B Financing



June 17, 2014
True North snags $22M and sets course for the clinic with a rare disease drug



April 29, 2014
iPierian acquired by Bristol-Myers Squibb
Advances discovery strategy to pursue therapeutics for genetically defined diseases


April 16, 2014
Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program
William Greene, MD, Appointed Chief Executive Officer


April 14, 2014
Celladon Receives Breakthrough Therapy Designation from FDA
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDA’s Center for Biologics Evaluation and Research (CBER)


February 18, 2014
CoStim Pharmaceuticals, Inc. Acquired by Novartis



January 27, 2014
MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs



January 7, 2014
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone





2017
2016
2015
2014











X










X










X










































 




MPM BioVentures III, L.P.: Private Company Information - Bloomberg









































  





















































































July 22, 2017 8:57 PM ET
Capital Markets

Company Overview of MPM BioVentures III, L.P.



Snapshot People




Company Overview
MPM BioVentures III, L.P. specializes in early, mid-stage, late-stage, and PIPE investments. The fund focuses on healthcare, biotechnology, pharmaceutical, medical device, and platform technology companies. 85 percent of its investments is focused on biotechnology and pharmaceutical products and 15 percent is focused on medical devices and the life science tool segment. The fund seeks to invest in the United States, Europe, and Asia. The fund prefers to invest between $15 million and $25 million per transaction.


450 Kendall StreetCambridge, MA 02142United StatesFounded in 2000



Phone: 617-425-9200

Fax: 617-425-9201








Key Executives for MPM BioVentures III, L.P.




Dr. Ansbert K. Gadicke M.D., Ph.D.


      	Managing Director and Co-Founder
      


Age: 59
        







Dr. Luke B. Evnin Ph.D.


      	Co-Founder, Managing Director and Managing Partner
      


Age: 54
        




Compensation as of Fiscal Year 2017. 



Similar Private Companies By Industry



Company Name
Region



 @Visory LLC United States 1 Road Partners LLC United States 11T Partners, LLC United States 123Jump.com, Inc. United States 1509225 Ontario, Inc. United States




Recent Private Companies Transactions



TypeDate
Target



No transactions available in the past 12 months.




Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States Bertelsmann AG Europe The Advertising Council, Inc. United States Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact MPM BioVentures III, L.P., please visit --.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


























